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Summary 
Expansion	of	CAG	repeats	in	genes	leads	to	debilitating	human	disorders	characterized	by	protein	
aggregation	 due	 to	 the	 corresponding	 polyglutamine	 (polyQ)	 tract	 in	 proteins	 leading	 to	
neurodegeneration.	 The	mechanism	of	 aggregation	 involves	 primary	 and	 secondary	 nucleation	
steps	and	we	show	how	a	non-canonical	member	of	the	DNAJ-chaperone	family,	DNAJB6,	inhibits	
the	 conversion	 of	 soluble	 polyQ	 peptides	 into	 amyloid	 fibrils	 by	 strongly	 suppressing	 primary	
nucleation.	This	inhibition	is	mediated	by	a	conserved	serine/threonine-rich	region	in	DNAJB6	that	
provides	an	array	of	surface-exposed	hydroxyl	groups	that	can	bind	to	polyQ	peptides	and	disrupt	
the	 formation	 of	 H-bonds	 that	 are	 essential	 for	 the	 stability	 of	 amyloid	 fibrils.	 We	 show	 in	
addition	that	the	early	prevention	of	polyQ	aggregation	by	DNAJB6	also	occurs	in	living	cells	and	
leads	 to	delayed	neurite	 retraction	even	before	aggregates	are	visible.	 Importantly,	 in	a	mouse	
model,	brain-specific	co-expression	of	DNAJB6	delays	polyQ	aggregation	and	relieves	symptoms	
and	prolongs	life	span.	DNAJB6	is	therefore	both	a	potential	target	for	disease	therapy	and	a	tool	
for	unraveling	the	early	events	in	the	onset	of	polyQ	diseases.	
	
	
	
	
	
	
	
	
	
	
	
Highlights:		
• the	chaperone	DNAJB6	inhibits	polyQ	aggregation	at	sub-stoichiometric	ratios	
• DNAJB6	inhibits	primary	nucleation	and	formation	of	amyloid	fibrils		
• DNAJB6	functionality	depends	on	hydroxyl	groups	in	a	unique	serine/threonine-rich	motif	
• DNAJB6	reduces	aggregation,	delays	symptoms	and	prolongs	life	span	in	polyQ	mice		
	
	
eTOC	Blurb:		
Insights	 into	 the	 mechanism	 by	 which	 DNAJB6,	 a	 member	 of	 the	 DNAJ-family	 of	 molecular	
chaperones,	 inhibits	 early	 steps	 in	 the	 formation	 of	 polyglutamine	 amyloid	 fibrils.	 A	 unique	
serine/threonine	(S/T)-rich	region	 in	DNAJB6	that	exposes	an	array	of	hydroxyl	groups	 is	crucial	
for	 inhibition	of	amyloid	 formation.	Activity	 is	gradually	 lost	 in	S/T-to-A	substitution	variants	of	
DNAJB6	 both	 in	 vitro	 and	 in	 cells.	 In	 a	 polyglutamine	mouse	model	 these	 inhibitory	 effects	 of	
DNAJB6	result	in	a	delay	in	disease	onset	and	in	increased	lifespan.		
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Introduction 
In	 trinucleotide	 (CAG)	 repeat	 expansion	 disorders,	 which	 include	 Huntington’s	 disease	 (HD),	
spinocerebellar	 ataxias	 (SCAs)	 and	 spinal	 and	 bulbar	 muscular	 atrophy	 (SBMA),	 proteins	
containing	 polyglutamine	 (polyQ)	 stretches	 promote	 protein	 aggregation	 and	 formation	 of	
pathological	 structures	 such	 as	 amyloid	 fibrils	 and	 their	 precursors	 (Chiti	 and	 Dobson,	 2006;	
Zoghbi	 and	Orr,	 2000).	 The	 length	 of	 the	 polyQ	 expansion	 is	 strongly	 linked	with	 aggregation	
propensity,	 and	 is	 also	 inversely	 correlated	with	 the	 age	 at	 onset	 of	 the	 disease	 (Gusella	 and	
MacDonald,	2000).	These	findings	strongly	suggest	that	aggregate	formation	triggers	disease.	Yet	
the	mechanism	of	 aggregation,	 the	 surface	 properties	 and	 interactions	 of	 the	 aggregates,	 and	
even	the	mechanistic	connection	between	aggregation	and	the	onset	of	neurodegeneration	are	
not	well	understood.	Several	lines	of	evidence	suggest	that	it	is	not	the	full	length	polyQ	proteins	
that	are	aggregation	prone,	but	rather	that	aggregation	is	 initiated	by	smaller	pieces	of	the	full	
length	proteins,	which	arise	either	from	alternative	splicing	(Ramani	et	al.,	2015;	Sathasivam	et	
al.,	2013)	or	as	a	result	of	protease	activation	by	excitotoxic	events	(Graham	et	al.,	2006;	Koch	et	
al.,	 2011;	 Raspe	 et	 al.,	 2009).	 The	 proteolytic	 parts	 of	 the	 protein	 containing	 the	 polyQ	
expansions	can	either	directly	or	after	further	processing	via	the	proteasome	into	polyQ-peptides	
(Raspe	et	al.,	2009;	Venkatraman	et	al.,	2004),	promote	the	subsequent	aggregation	of	the	full-
length	 polyQ	 proteins	 and	 of	 other	 Q-stretch	 containing	 proteins,	 including	 a	 range	 of	
transcription	factors	(Suhr	et	al.,	2001;	Venkatraman	et	al.,	2004;	Waelter	et	al.,	2001).	Indeed,	
sequestration	within	 these	 aggregates	 of	 essential	 transcription	 factors,	 or	 of	 chaperones	 and	
proteasome	 components	 (Park	 et	 al.,	 2013;	 Raspe	 et	 al.,	 2009),	 appears	 to	 be	 one	 of	 the	 key	
pathogenic	events	that	contribute	to	the	functional	impairment	of	neurons.	
Molecular	chaperones	generally	maintain	protein	homeostasis	 in	cells	 (Hipp	et	al.,	2014).	
Some	 can	 bind	 to	 unfolded	 polypeptides	 and	 assist	 their	 folding	 and	 assembly,	 thereby	
suppressing	non-productive	protein-protein	 interactions	 and	aggregate	 formation	 (Balch	et	 al.,	
2008).	Several	chaperones	are	upregulated	upon	acute	stress	in	a	process	referred	to	as	the	heat	
shock	 response	 (HSR)	 and	 that	 is	 controlled	 by	 the	 heat	 shock	 transcription	 factor-1	 (HSF-1)	
(Akerfelt	et	al.,	2010).	A	finding	that	supports	the	specific	proposition	that	protein	aggregation	is	
a	major	factor	driving	polyQ	diseases	 is	that	activation	of	HSR	delays	phenotypic	changes	 in	fly	
and	worm	models	of	polyQ	diseases	(Fujikake	et	al.,	2008;	Neef	et	al.,	2010;	Warrick	et	al.,	1998).	
Aggregate	 formation	 is,	 however,	 not	 always	 observed	 to	 be	 reduced	 under	 such	 conditions	
(Warrick	et	al.,	1998),	and	in	mouse	models	of	polyQ	diseases	the	activation	of	HSR	(Labbadia	et	
al.,	 2011),	 or	 the	 transgenic	 expression	 of	 individual	 chaperones	 such	 as	 HSPA1A	 (Hsp70)	
(Hansson	et	al.,	2003;	Hay	et	al.,	2004)	and	HSPB1	(Hsp27)	(Zourlidou	et	al.,	2007),	has	generally	
not	been	found	to	delay	disease	onset	or	reduce	aggregate	formation.	Moreover,	the	expression	
of	 polyQ	 proteins	 per	 se	 does	 not	 activate	 the	 HSR,	 implying	 that	 the	 protein	 quality	 control	
(PQC)	system	does	not	respond	to	the	presence	of	the	protein	with	the	polyQ	expansion	(Seidel	
et	al.,	2012);	this	finding	may	explain	why	the	canonical	chaperones	have	been	so	disappointingly	
ineffective	 in	 polyQ	 diseases.	 There	 are	 also	 members	 of	 the	 diverse	 families	 of	 molecular	
chaperones	 that	 are	 not	 controlled	 by	 the	 classical	 HSR	 (Vos	 et	 al.,	 2008)	 that	 may	 serve	 in	
alternative	pathways	for	PQC,	and	so	help	to	counteract	polyQ	diseases.	Indeed,	in	a	dedicated	
screen	for	polyQ	modifiers	(Hageman	et	al.,	2010)	we	discovered	such	members,	the	two	close	
homologues	of	the	DNAJ	chaperone	family,	DNAJB6	and	DNAJB8,	both	of	which	are	oligomeric	in	
their	 functional	 states	 and	 non-canonical	 in	 their	mode	 of	 action	 (Kampinga	 and	 Craig,	 2010).	
DNAJB8	(expressed	in	the	testis)	and	DNAJB6	(expressed	in	several	tissues	and	especially	in	the	
brain)	 were	 found	 to	 be	 very	 efficient	 suppressors	 of	 polyQ	 aggregation	 in	 cell	 models,	
irrespective	of	the	protein	context	in	which	these	expansions	reside,	either	huntingtin	exon-1	or	
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a	 full	 length	 ataxin	 3	 or	 the	 androgen	 receptor	 (Hageman	 et	 al.,	 2010).	 Efficient	 inhibition	 of	
aggregation	initiated	by	polyQ	peptides	has	been	observed	to	occur	both	in	cell	free	(Månsson	et	
al.,	2014a)	and	in	cellular	models	(Gillis	et	al.,	2013).	Yet,	the	mode	of	action	for	the	remarkable	
efficiency	of	DNAJB6	as	a	 suppressor	molecule	 is	not	understood,	nor	whether	 it	 translates	 to	
protection	in	vivo.		
Here,	we	have	addressed	 the	 following	key	questions	concerning	 the	mechanism	of	how	
DNAJB6	 can	 inhibit	polyQ	aggregation	 so	efficiently:	How	does	DNAJB6	 influence	aggregation?	
What	features	of	DNAJB6	make	it	so	special	compared	to	other	chaperones?	Is	the	inhibition	of	
polyQ	 aggregation	 by	 DNAJB6	 of	 any	 relevance	 for	 disease	 also	 in	 a	mammalian	 system?	We	
show	that	analysis	of	the	kinetics	of	aggregation	reveals	the	fact	that	DNAJB6	inhibits	early	steps	
in	the	formation	of	amyloid	fibrils,	and	that	the	 inhibition	activity	 is	mediated	by	a	unique	and	
conserved	 serine/threonine	 (S/T)-rich	 region.	 In	 addition,	we	 show	 that	 this	 inhibition	 activity	
translates	 into	 the	 prevention	 of	 neurite	 retraction,	 even	 prior	 to	 formation	 of	 inclusions	 in	
neuronal	cells.	Furthermore,	 in	a	mouse	model	of	polyQ	disease	that	exhibits	 the	most	 rapidly	
progressing	features	of	polyQ	pathogenicity	we	show	that	DNAJB6	delays	the	onset	of	disease,	
reduces	the	severity	of	its	consequences	and	significantly	prolongs	lifespan.		
	
Results 
DNAJB6	inhibits	primary	nucleation	of	polyQ	peptides.	
In	order	to	assess	the	mechanism	by	which	DNAJB6	 inhibits	 the	aggregation	of	different	polyQ	
containing	proteins,	we	 studied	 formation	of	amyloid	 fibrils	 from	a	widely	used	6.5	kDa	polyQ	
peptide	 (sequence	 GAMKSFQ45F)	 by	 monitoring	 the	 kinetic	 profiles	 of	 the	 thioflavin	 (ThT)	
fluorescence	 changes	 (Månsson	 et	 al.,	 2014a).	 Identification	 of	 the	microscopic	mechanism	of	
protein	aggregation	from	the	analysis	of	the	corresponding	macroscopic	kinetic	profiles	is	based	
on	 the	 fact	 that	 the	 formation	 of	 amyloid	 fibrils	 is	 the	 consequence	 of	 a	 series	 of	 specific	
processes,	 including	 primary	 nucleation,	 fibril	 elongation,	 fibril	 fragmentation	 and	 secondary	
nucleation,	 all	 of	 which	 are	 associated	with	 individual	 reaction	 rate	 constants.	Moreover,	 the	
time	 evolution	 of	 fibril	 formation	 can	 be	 described	 by	 a	 master	 equation	 that	 includes	 the	
contributions	of	 the	various	 individual	microscopic	processes	 (Arosio	et	al.,	2014;	Cohen	et	al.,	
2011a,	 2011b).	 The	 data	 obtained	 by	 analysis	 of	 the	 kinetics	 of	 the	 aggregation	 reaction	 at	
different	concentrations	of	the	polyQ	peptide	(Fig.	1A)	indicate	that	secondary	nucleation	plays	a	
key	role	 in	polyQ	peptide	aggregation,	and	in	the	generation	of	the	oligomeric	species	that	are	
likely	 to	 be	 the	primary	 agents	 of	 cellular	 toxicity.	Next,	 the	 aggregation	profiles	 of	 the	polyQ	
peptide	in	the	presence	of	DNAJB6	were	analyzed	(Fig.	1B,	C).	The	experimental	measurements	
show	 that	 DNAJB6	 substantially	 delays	 the	 aggregation	 reaction	 by	 increasing	 the	 lag-time	 of	
aggregation,	without	a	detectable	effect	on	the	growth	phase	of	the	aggregation	reaction	(note	
the	parallel	curves	 in	Fig	1B,	C).	The	rate	constants	determined	from	the	kinetic	analysis	reveal	
the	microscopic	events	that	underlie	the	macroscopic	inhibition	of	the	aggregation	process,	and	
shows	that	DNAJB6	strongly	inhibits	the	primary	nucleation	step	in	the	aggregation	process	and	
that	modeling	this	effect	most	closely	describes	its	mechanism	of	action	(Fig.	1B).	At	a	molar	ratio	
of	 polyQ	 peptide	 to	 DNAJB6	 monomer	 of	 1:0.1,	 the	 data	 indicate	 that	 the	 rate	 of	 primary	
nucleation	is	reduced	by	a	factor	of	109	(Fig.	1F,	black	bar).	However,	DNAJB6	also	perturbs	the	
secondary	nucleation	process,	even	though	to	a	much	smaller	degree.	Whereas	this	effect	alone	
cannot	well	describe	 its	 full	mechanism	of	 action	 (Fig.	 1C),	 secondary	nucleation	 rates	are	 still	
reduced	by	 a	 factor	 of	 50	 in	 the	presence	of	DNAJB6	 at	 1	 1:0.1	 ratio	 (Fig.	 1G,	 black	 bar).	 The	
effects	on	secondary	nucleation	pathways	are	further	supported	by	additional	analysis	of	seeded	
aggregation	 reaction	 (Fig.	 S1):	 adding	 polyQ	 fibrils	 to	 the	 reaction	 enhances	 monomer	
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aggregation	(Fig	S1A)	and	DNAJB6	can	also	slow	down	these	reactions,	the	magnitude	depending	
on	 the	percentage	of	 seeds	added	 (Fig.	 S1B).	 Including	both	effects	on	primary	and	 secondary	
nucleation	steps	actually	 leads	to	an	excellent	 fit	of	 the	experimental	data	 (Fig	1G,	black	curve	
underneath	green	curve:	see	also	next	section).	To	see	whether	DNAJ6B	also	delays	aggregation	
at	sub-stochiometric	ratios	in	another	disease-relevant	context,	the	analysis	was	also	performed	
with	a	14	kDa	Htt-Exon	1	construct	where	the	N-terminus	contributes	to	the	primary	aggregation	
step,	yielding	qualitatively	similar	data	(Fig.	S2).	This	analysis	shows	hat	DNAJB6	is	most	likely	to	
interfere	with	the	nucleation	steps	in	aggregation	by	sequestering	either	the	monomeric	polyQ	
species	or	the	small	oligomeric	species	that	are	generated	in	the	key	initial	stages	of	the	reaction.	
Given	that	the	inhibitory	effects	of	DNAJB6	are	substantial,	even	at	very	low	sub-stoichiometric	
ratios,	such	sequestration	cannot	simply	be	a	consequence	of	binding	to	the	monomeric	species.	
We	conclude	therefore	that	DNAJB6	interacts	with	the	oligomeric	species	formed	by	the	primary	
nucleations.		
	
Loss	of	inhibition	activity	in	S/T	substitution	mutational	variants	of	DNAJB6.	
Our	previous	cell	biological	data	revealed	the	likely	importance	of	a	conserved	serine-threonine	
(S/T)	rich	region	in	the	potent	anti-aggregation	effects	of	DNAJB6.	Deletion	of	this	region	resulted	
in	 the	 loss	 of	 anti-aggregation	 activity,	 and	 also	 to	 loss	 of	 HDAC	 binding	 and	 the	 oligomeric	
conformation	found	in	cells	(Hageman	et	al.,	2010),	and	as	isolated	purified	protein	(Månsson	et	
al.,	2014a).	This	conserved	region	in	DNAJB6	contains	many	hydroxyl	groups	in	the	side	chains	of	
the	 S/T-residues.	 Since	 the	 low	molecular	weight	 compound	 EGCG,	 a	 potent	 inhibitor	 of	 fibril	
formation,	 contains	 exposed	 hydroxyl	 groups,	 which	 have	 been	 proposed	 to	 engage	 in	
establishing	intramolecular	hydrogen	bonding	with	polyQ	peptides	(Ehrnhoefer	et	al.,	2006),	and	
hydroxyl	 groups	 in	 conserved	 tyrosine	 residues	 of	 the	 Brichos	 chaperone	 are	 important	 for	
inhibiting	 amyloid	 formation	 (Willander	 et	 al.,	 2012).	 In	 order	 to	 explore	 the	 potential	
importance	 of	 the	 hydroxyl	 groups	 in	 the	 S/T-rich	 region	 of	 DNAJB6	 for	 its	 ability	 to	 inhibit	
aggregation	we	therefore	generated	a	set	of	mutational	variants	(Fig.	1D)	in	which	6,	13	or	18	S/T	
residues	were	substituted	by	alanine	residues	(referred	to	as	S/T-to-A)	and	one	variant	in	which	
the	entire	S/T-rich	region	was	deleted.	Purified	DNAJB6	(Fig.	S3A)	forms	oligomers	which	appear	
highly	dynamic	since	the	subunits	exchange	on	a	time-scale	of	hours	(Fig.	S3B).	 In	contrast,	the	
DNAJB6	variant	M4	 in	which	 the	entire	S/T-region	 is	deleted	 is	 structurally	perturbed,	and	 the	
oligomeric	conformation	is	lost	(Fig.	S3C)	as	was	previously	seen	in	cells	(Hageman	et	al.,	2010),	
implying	 that	 M4	 cannot	 be	 used	 to	 determine	 the	 functionality	 of	 the	 S/T-region	 per	 se.	
However,	all	 the	mutational	variants	M1-M3,	with	 increasing	number	of	S/T-to-A	substitutions,	
remain	oligomeric	as	judged	by	native	PAGE	(Fig.	S3C),	and	are	also	structurally	intact	as	judged	
by	CD-spectroscopy	(Fig.	S3D).	That	M3,	the	mutational	variant	of	DNAJB6	with	largest	number	
of	S/T-to-A	substitutions,	is	oligomeric	was	also	confirmed	by	size	exclusion	chromatography	(Fig.	
S3E):	 only	 a	 minor	 shift	 in	 the	monomer-oligomer	 equilibrium	was	 found	 when	 compared	 to	
wildtype	DNAJB6.	From	the	ThT	fluoresence	measurements	it	was	evident	that	the	function,	i.e	
the	aggregation	 inhibition	 capacity	of	 the	wildtype	DNAJB6,	declined	declined	as	 a	 function	of	
the	number	of	S/T-to-A	substitutions	and	was	almost	completely	 lost	when	all	18	S/T	 residues	
are	substituted	with	A	residues	(Fig.	1E,	Fig	S5).	Detailed	analysis	of	the	aggregation	kinetics	(Fig	
1F,	G)	 revealed	 that	 the	 S/T-to-A	 substitutions	 affected	 the	 ability	 to	 inhibit	 both	primary	 and	
secondary	steps	in	the	aggregation	reactions.		
Structural	modeling	of	DNAJB6	(Fig.	S4)	suggested	that	the	array	of	18	side-chain	hydroxyl	
groups	 are	 exposed	 on	 one	 face	 of	 the	 DNAJB6	monomer	 (Fig.	 1H,	 highlighted	 in	 pink).	 That	
these	exposed	hydroxyl	groups	 indeed	affect	 the	binding	of	DNAJB6	to	polyQ	 is	suggested	 in	a	
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filter	trap	assay	where,	after	completed	ThT	fluorescence	measurements	(Fig.	1E),	the	content	in	
the	wells	of	the	microtiter	plate	was	collected,	put	onto	a	filter,	washed	with	0.1%	SDS	such	that	
only	polyQ	fibrils	stay	on	filter	and	probed	for	the	presence	of	DNAJB	with	immunofluorescence	
(Fig.	1I).	Quantitation	of	 the	 immunofluorescence	data	 indicate	 that	 the	mutational	variants	of	
DNAJB6	without	the	S/T-rich	region	were	to	a	smaller	extent	binding	and	captured	into	the	polyQ	
fibrils	during	their	formation,	compared	to	wildtype	DNAJB6	(Fig.	1J).	Taken	together,	the	data	in	
Fig.	1	demonstrate	that	the	unique	S/T-rich	region	 in	DNAJB6	 is	crucial	 for	 its	ability	to	bind	to	
polyQ	peptides	and	inhibit	their	primary	nucleation.	
	
DNAJB6	prevents	initiation	of	polyQ	aggregation	within	cells.		
In	order	to	explore	the	stage	of	the	reaction	at	which	DNAJB6	affects	aggregation	within	cells,	we	
compared	 its	 effects	 on	 the	 aggregation	 of	 intracellular	 polyQ	 and	 assessed	 how	 this	 is	
accelerated	 by	 an	 extracellular	 addition	 to	 the	 media	 of	 polyQ	 peptides	 in	 aggregated	 and	
fibrillar	 forms.	 Such	 species	 can	 be	 taken	 up	 by	 cells	 and	 released	 into	 the	 cytosol,	 by	 as	 yet	
unknown	mechanisms,	where	they	can	then	act	as	seeds	for	aggregation	of	both	expanded	and	
non-expanded	polyQ	proteins	in	the	recipient	cells	(Ren	et	al.,	2009).	An	eGFP-tagged	exon-1	of	
the	huntingtin	protein	with	a	non-pathogenic	Q	stretch	(HttQ23-eGFP)	was	expressed	in	cells	and	
formed	no	aggregates	 spontaneously	within	48	h	 (Fig.	2B-D),	but	aggregation	was	observed	 to	
occur	during	3-48	h	following	extracellular	addition	of	polyQ	peptides	in	aggregated	and	fibrillar	
form	 (Fig.	 2A,	 2C-E),	 referred	 to	 as	 [Q45	 seed]extra	 (Fig.	 2C-E).	 DNAJB6	 almost	 completely	
suppressed	aggregation	initiated	intracellularly	by	eGFP-tagged	exon-1	of	the	huntingtin	protein	
with	 a	 pathogenic	 Q	 stretch	 ([Htt-Q74-eGFP]intra)	 without	 such	 extracellular	 addition	 of	 seeds	
(Fig.	 2D,	 lower	 panel),	 whereas	 DNAJB6	 was	 found	 to	 only	 slightly	 delay	 aggregation	 of	
intracellular	HttQ23-eGFP	 following	 addition	of	 seeds.	 This	 finding,	 summarized	 in	 Fig.	 2E	 as	 a	
comparison	between	the	left	panel	(Htt	exon	1-Q74,	no	seeds)	and	right	panel	(Htt	exon-1	Q23,	
extracellular	Q45	seeds),	indicates	that,	also	in	cells,	DNAJB6	primarily	delays	the	initial	processes	
in	aggregate	formation	which	are	circumvented	by	addition	of	extracellular	polyQ	seeds	and	are	
in	line	with	our	data	showing	inhibition	of	key	initial	stages	of	the	polyQ	aggregation	by	DNAJB6	
protein	in	vitro	(Fig.	1).	
	
S/T	substitutions	in	DNAJB6	also	reduce	anti-aggregation	potential	in	living	cells.	
To	test	whether	the	S/T-rich	region	is	crucial	for	the	protective	effects	of	DNAJB6	also	within	the	
crowded	 environment	 of	 living	 cells,	 we	 expressed	 exon-1	 of	 the	 huntingtin	 protein	 with	 an	
expanded	 polyQ	 stretch	 (Htt-Q119-eYFP)	 in	 HEK293	 cells	 and	 compared	 the	 results	 with	 or	
without	co-expression	of	wildtype	DNAJB6	or	the	S/T-substitution	variants.	These	data	showed,	
in	 close	 similarity	 to	 the	 observations	 in	 the	 in	 vitro	 experiments	 with	 purified	 mutational	
variants	of	the	DNAJB6	protein	(Fig.	1),	that	the	anti-aggregation	capacity	of	DNAJB6	was	found	
to	decline	with	the	number	of	S/T	substitutions	in	DNAJB6	also	in	cells,	by	counting	the	fraction	
of	cells	with	 inclusions	 (Fig.	3	A,	D),	and	by	measuring	 the	 formation	of	high	molecular	weight	
aggregates,	using	SDS-PAGE	(Fig.	3	B,	E)	and	through	a	filter	trap	assay	(Fig.	3	C,	F).		
	
DNAJB6	reduces	neurite	retraction	 in	neuronal	cells	even	before	visible	aggregate	formation.	
We	next	evaluated	whether	DNAJB6	can	suppress	polyQ	aggregation	and	reduce	the	associated	
toxic	effects	 in	neuronal	cells.	We	therefore	expressed	polyQ	 in	differentiated	NG108	cells	and	
compared	 the	 results	with	or	without	 co-expression	of	DNAJB6.	Analysis	 of	 polyQ	aggregation	
using	 the	 filter	 trap	assay	 (Fig.	4A,	B)	or	by	measuring	 the	 formation	of	high	molecular	weight	
aggregates,	 using	 SDS-PAGE	 (Fig.	 S6A,	 B)	 showed	 that	 in	 cells	 co-expressing	 DNAJB6,	 polyQ	
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aggregate	formation	was	strongly	suppressed	with	a	concomitant	increase	in	the	level	of	soluble	
polyQ	(Fig.	3A,	B).	Immunofluorescence	(IF)	and	live	cell	imaging	revealed	that	aggregates	initially	
appeared	in	and	around	the	soma	of	the	cells	and	then,	at	later	time-points,	were	also	found	in	
the	 neurites	 (Fig.	 4C,	 Fig.	 S6C).	 Cells	 with	 Htt-Q119-eYFP	 inclusions	 (IF-detectable	 aggregates)	
had	fewer	processes	(Fig.	4D).	Cells	expressing	Htt-Q23-GFP	(a	non-pathogenic	polyQ	stretch,	in	
contrast	to	the	pathogenic	expanded	polyQ	stretch	in	Htt-Q119-eYFP)	were	unaffected	(data	not	
shown),	 demonstrating	 that	 the	 observed	 effects	 were	 indeed	 due	 to	 the	 expanded	 polyQ	
stretch.	In	cells	with	Htt-Q119-eYFP	inclusions,	there	were	on	average	2.0	processes/cell	without	
DNAJB6;	 in	 the	 few	 cells	 showing	 inclusions	 when	 co-expressing	 DNAJB6	 this	 number	 was	
significantly	 higher	 (4.1	 processes/cell).	 Importantly,	 DNAJB6	 co-expression	 increased	 the	
number	 of	 processes	 also	 in	 cells	 without	 detectable	 aggregates	 (2.1	 processes/cell	 without	
DNAJB6;	5.7	processes/cell	with	DNAJB6)(Fig.	4C,	D).	In	addition,	FRAP	analysis	(Fig.	S7)	revealed	
that	the	mobility	of	the	otherwise	diffusely	distributed	Htt-Q119-eYFP,	in	areas	within	the	cytosol	
but	 outside	 inclusions,	 was	 reduced	 compared	 to	 a	 GFP	 control	 and	 increased	 in	 cells	 co-
expressing	DNAJB6.	These	findings	are	consistent	with	the	direct	action	of	DNAJB6	prior	to	the	
formation	of	visible	inclusions,	on	species	formed	at	very	early	stages	in	the	aggregation	process.	
In	line	with	its	loss	of	anti-aggregation	activity	(Fig.	1,	4),	the	M3	mutational	variant	with	18	S/T-
to-A	substitutions	was	unable	to	protect	against	polyQ-mediated	loss	of	processes	(Fig.	4	C,	D).	
	
DNAJB6	binds	to	polyQ	via	its	S/T-rich	region	in	cells	and	requires	its	J-domain	for	interaction	
with	HSP70	and	full	activity	
To	 confirm	 early	 interaction	 of	 DNAJB6	 with	 soluble,	 non-aggregated	 polyQ	 species	 we	
performed	co-immunoprecipitation	 in	NP40	 soluble	 cell	 lysates.	 Indeed,	 significant	amounts	of	
polyQ	were	immunoprecipitated	with	DNAJB6	(Fig	5A).	Near	to	no	co-immunoprecipitation	with	
the	M3	mutational	variant	with	18	S/T-to-A	substitutions,	which	was	unable	 to	protect	against	
polyQ-mediated	loss	of	processes,	was	observed	(Fig.	5A)	confirming	the	in	vitro	data	(Fig.	1I,	J)	
that	 the	 S/T-rich	 is	 crucial	 for	 substrate	 binding	 and	 hence	 the	 anti-aggregation	 function	 of	
DNAJB6.		
	 DNAJ	proteins	are	usually	thought	to	function	through	interaction	with	Hsp70,	i.e.	within	
the	context	of	the	Hsp70	machinery.	There	is	a	histidine-proline-aspartate	(HPD)	motif	within	the	
J-domain	 which	 is	 crucial	 for	 DNAJ-Hsp70	 functional	 interactions	 (Kampinga	 and	 Craig,	 2010).	
Indeed,	DNAJB6	can	interact	with	the	Hsp70	family	member	HSPA1A	in	cells,	as	revealed	by	co-
immunoprecipitation	 analyses	 (Fig.	 5B),	 whereas	 a	 mutant	 carrying	 a	 substitution	 in	 the	
conserved	 HPD	 domain	 (H31Q:	 converting	 this	 motif	 from	 HPD	 to	 QPD)	 completely	 loses	 its	
ability	 to	 interact	 with	 HSPA1A.	 In	 contrast,	 the	 M3	 mutational	 variant	 with	 18	 S/T	 >	 A	
substitutions	still	fully	retained	is	ability	to	interact	with	HSPA1A	(Fig.	5B),	further	supporting	the	
in	 vitro	 data	 (Fig	 S3)	 that	 these	 substitutions	 had	 not	 affected	 the	main	 structural	 features	 of	
DNAJB6.	For	wildtype	DNAJB6,	the	H31Q		mutation	had	been	shown	to	only	marginally	affect	the	
ability	of	DNAJB6	to	delay	polyQ	aggregation	in	cells	(Hageman	et	al.,	2010).	Such	independency	
of	Hsp70	is	also	observed	in	vitro	with	no	enhanced	effect	by	addition	of	Hsp70	into	the	reaction	
mixture	 with	 DNAJB6	 (Månsson	 et	 al.,	 2014a).	 However,	 given	 the	 very	 efficient	 protection	
against	polyQ	aggregation	at	extremely	low	stoichiometry,	we	hypothesized	that	the	capacity	of	
wildtype	 DNAJB6	 to	 bind	 to	 substrates	 in	 cells	 may	 not	 have	 been	 sufficiently	 challenged	 to	
reveal	such	Hsp70	dependency.	To	address	this	issue	further,	we	introduced	an	H/Q	mutation	in	
the	DNAJB6	mutational	variant	M2	(13	S/T-to-A	substitutions,	see	Fig.	1F)	which	had	considerably	
reduced,	but	still	some	residual	anti-aggregation	activity	compared	to	wildtype	DNAJB6,	both	in	
vitro	(Fig.	1)	and	when	expressed	in	cells	(Fig.	3).	This	double	mutant,	with	the	QPD-mutation	in	
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the	 already	 impaired	 M2	 mutational	 variant	 of	 DNAJB6,	 showed	 an	 almost	 complete	 loss	 of	
inhibitory	 activity,	 whereas	 the	 QPD-mutation	 in	 the	 wildtype	 DNAJB6	 still	 inhibited	 polyQ	
aggregation	to	75%	(Fig.	5C-H).	This	result	implies	that	DNAJB6	is	a	bona-fide	DNAJ	protein	that	
in	 principle	 has	 the	 capability	 to	 bind	 to	 and	 collaborate	 with	 Hsp70,	 although	 such	 Hsp70	
interaction	is	required	only	under	conditions	where	the	DNAJB6	capacity	is	 limited.	Under	such	
conditions	 Hsp70	 might	 be	 required	 to	 assist	 in	 release	 of	 the	 substrate	 peptides	 bound	 to	
DNAJB6	and	thereby	recycle	DNAJB6.	In	line,	we	find	that	the	H/Q	mutant	of	DNAJB6	pulls-down	
more	polyQ	than	wildtype	DNAJB6	(Fig	5A).	
In	summary,	the	combined	data	with	purified	proteins	(Fig.1)	and	in	diverse	cellular	models	
(Fig.	2-5)	suggest	a	model	in	which	DNAJB6	strongly	suppresses	primary	nucleation	and	identifies	
the	S/T-rich	region	as	a	functional	(sub)domain	in	the	DNAJB6	protein	that	is	responsible	for	its	
chaperone	 activity.	 The	 ability	 of	 DNAJB6	 to	 inhibit	 aggregation	 of	 polyQ	 containing	 proteins	
relies	on	direct	 interaction	with	the	substrate,	the	polyQ	stretch	 itself,	an	ability	that	canonical	
chaperones	 –	 that	 mainly	 recognize	 hydrophobic	 regions	 –	 seem	 to	 lack.	 This	 explains	 why	
DNAJB6	is	a	much	more	potent	inhibitor	of	polyQ	aggregation	than	other	chaperones,	including	
several	other	members	of	the	DNAJ	protein	class,	that	have	so	far	been	investigated	(Hageman	
et	al.,	2010).	
	
Brain-specific	 DNAJB6	 expression	 reduces	 aggregation	 and	 delays	 disease	 onset	 in	 a	
polyglutamine	mouse	model.	
To	 study	whether	or	not	 the	highly	protective	effects	of	DNAJB6	observed	 in	 vitro	 and	 in	 cells	
also	 translate	 into	 neuro-protection	 in	 vivo,	 we	 generated	 transgenic	 mice	 that	 express	 the	
human	DNAJB6	under	control	of	the	brain-specific	nestin	promotor	(Fig.	6A),	with	no	significant	
expression	 in	 other	 tissues	 (Fig.	 6B,	 C).	 DNAJB6	 transgenic	 mice	 were	 born	 in	 the	 expected	
Mendelian	ratios	and	did	not	show	any	overt	phenotype.	The	expression	of	the	human	DNAJB6	
transgene	 did	 not	 affect	 the	 expression	 of	 the	 endogenous	mouse	 DNAJB6	 nor	 of	 any	 of	 the	
other	DNAJs	analyzed	(Fig.	S8).	In	addition,	the	HSPA1A	(the	stress-regulated	Hsp70)	levels	were	
unaltered	 in	 brain	 and	 muscle	 lysates	 from	 the	 transgenic	 mice	 (Fig.	 S9)	 showing	 that	
overexpression	of	DNAJB6	does	not	induce	a	general	stress	response.	
Next,	 the	DNAJB6	transgenic	mice	were	crossed	with	R6/2	mice	expressing	exon-1	of	the	
human	 huntingtin	 gene,	 containing	 201	 ±	 1	 CAG	 repeats:	 this	 R6/2	 model	 exhibits	 the	 most	
rapidly	 progressing	 features	of	 polyglutamine	pathogenicity	 in	 any	mouse	model	 and	 captures	
several	key	aspects	of	human	disease,	 including	early	onset	motor	dysfunction	associated	with	
the	 generation	 of	 protein	 aggregates	 in	 the	 brain,	 and	 a	 substantial	 reduction	 in	 lifespan	
(Mangiarini	et	al.,	1996;	Menalled	et	al.,	2009).	Whole	brain	lysates	from	R6/2	mice	(referred	to	
as	 HTT)	 and	 double	 transgenic	 (HTT/JB6)	mice	 were	 then	 compared	 at	 different	 ages	 for	 the	
presence	of	aggregates.	The	huntingtin	aggregates	in	brain	lysates	increased	over	time	in	the	HTT	
mice	(Fig.	6D)	in	accord	with	previous	studies,	but	the	aggregate	load	was	found	to	be	reduced	
significantly	(by	60%	and	30%	at	week	9	and	12,	respectively)	in	the	HTT/JB6	mice	co-expressing	
the	 DNAJB6	 transgene	 (Fig.	 6D,E).	 Moreover,	 Immunohistochemical	 analysis	 on	 paraffin-
embedded	 brain	 sections	 revealed	 an	 age-dependent	 increase	 in	 the	 formation	 of	 nuclear	
inclusions	 in	 the	striatum	of	 the	HTT	mice	 (Fig.	6D,	E)	but	not	 in	 the	WT	or	DNAJB6	transgenic	
mice	 (Fig.	 S10).	 Importantly,	 formation	 of	 inclusions	 in	 the	 brain	 was	 greatly	 reduced	 in	 the	
double	transgenic	HTT/JB6	mice	at	all	time-points	recorded	(Fig.	6D,	E).	Biochemical	detection	of	
aggregates	 (as	 high	molecular	 weight	 smears)	 in	 total	 brain	 lysates	 also	 showed	 reduction	 of	
aggregation	 in	HTT/JB6	mice	when	compared	 to	HTT	mice	 (Figure	S10A),	albeit	 that	 this	effect	
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was	less	pronounced	since	the	nestin	promoter	that	was	used	to	drive	expression	of	DNAJB6	is	
not	active	in	all	brain	areas.		
We	next	 investigated	the	effect	of	this	reduction	 in	aggregate	 load	 in	the	brain	on	motor	
(dysfunction)	symptoms.	In	agreement	with	earlier	data	(Mangiarini	et	al.,	1996;	Menalled	et	al.,	
2009),	 the	 HTT	 mice	 showed	 an	 early	 decline	 in	 rotarod	 performance,	 which	 progressively	
deteriorated	 with	 age.	 In	 the	 HTT/JB6	 double	 transgenic	 mice,	 however,	 this	 decline	 was	
substantially	delayed;	 for	example,	at	12	weeks	of	age	 the	 latency	 time	to	 fall	 for	 the	HTT/JB6	
mice	(45	s)	was	double	that	of	the	HTT	mice	(22	s)	(Fig.	7A).	Also,	both	hind	limb	(Fig.	7B)	and	full	
body	clasping	(Fig	7C)	observed	 in	the	HTT	mice	were	greatly	delayed	 in	the	double	transgenic	
HTT/JB6	mice;	70%	of	the	HTT	mice,	but	none	of	the	HTT/JB6	mice,	showed	full	body	clasping	at	
the	age	of	12	weeks.	Finally,	the	life	span	of	the	HTT/JB6	mice	was	extended	by	over	20%	when	
compared	to	that	of	the	HTT	mice	(Fig.	7D).	This	increase	in	life	span	is	even	more	remarkable	in	
view	of	the	fact	that	DNAJB6	expression	was	exclusively	elevated	in	parts	of	the	brain	and	not	in	
other	tissues	(Fig.	6B),	as	HD	aggregates	also	affect	skeletal	and	cardiac	muscle,	and	aggregation-
related	 progressive	 muscle	 atrophy	 has	 been	 reported	 to	 be	 a	 significant	 contributor	 to	 the	
impaired	motor	ability	 and	early	death	 in	 the	R6/2	model	 (Orth	et	 al.,	 2003;	Ribchester	et	 al.,	
2004;	 Sathasivam	 et	 al.,	 1999).	 We	 confirmed	 that	 aggregates	 were	 indeed	 present	 in	 the	
muscles	of	R6/2	mice	but,	 consistent	with	 the	brain	 specific	DNAJB6	expression,	 the	extent	of	
aggregation	in	quadriceps	skeletal	muscle	in	the	HTT/JB6	mice	was	found	to	be	similar	to	that	in	
the	 HTT	 mice	 (Fig.	 S11B).	 In	 addition,	 wasting	 effects,	 indicated	 by	 muscle	 weight	 loss,	 were	
found	 to	 be	 similar	 in	 both	 HTT	 and	 HTT/JB6	 mice	 (Fig.	 S11C).	 Since	 muscle	 waste	 likely	
contributed	 to	 the	 life	 span	 measurements,	 the	 potential	 protective	 effects	 of	 DNAJB6	 on	
lifespan	may	thus	be	even	greater	if	DNAJB6	expression	was	not	restricted	to	the	brain.		
	
Discussion 
Our	present	 findings	have	 identified	a	conserved	and	unique	S/T-rich	region	 in	DNAJB6,	a	non-
canonical	member	of	the	DNAJ-family	of	molecular	chaperones,	as	a	key	element	in	preventing	
polyQ	 aggregation	 and	 amyloid	 formation.	We	 show	how	 the	 capability	 of	 DNAJB6	 to	 directly	
interact	with	 polyQ	peptides	 translates	 into	 protection	 against	 detrimental	 effects	 of	 polyQ	 in	
cells	and	to	the	delayed	onset	of	aggregation	and	neurodegenerative	symptoms	in	polyQ	mice,	
ultimately	resulting	in	a	substantial	extension	of	their	lifespan.	
	
Conservation	of	polyQ-aggregation	behavior	from	in	vitro	to	in	vivo.	
The	kinetics	of	polyQ-aggregation	and	the	effects	on	them	of	DNAJB6	have	been	measured	at	a	
range	of	concentrations	enabling	us	to	utilize	the	framework	of	chemical	kinetics	of	the	data	for	
understanding	 the	 nature	 and	 rates	 of	 the	 specific	 microscopic	 steps	 in	 the	 mechanism	 of	
aggregation	(Arosio	et	al.,	2014;	Cohen	et	al.,	2015).	In	particular,	the	rate	of	primary	nucleation	
was	 found	to	be	significantly	 reduced	 in	 the	presence	of	DNAJB6	 (Fig.	1),	which	 is	expected	to	
delay	 the	 formation	of	aggregates	 in	vivo	and	to	reduce	the	population	of	 the	toxic	oligomers,	
particularly	at	early	time	points	(Arosio	et	al.,	2014;	Cohen	et	al.,	2015).	The	cellular	data	(Fig.	2-
5)	and	the	data	acquired	from	experiments	with	the	transgenic	mice	(Fig.	6,7)	are	in	agreement	
with	 this	 prediction,	 providing	 evidence	 that,	 in	 this	 polyQ	 system	 at	 least,	 the	 aggregation	
process	observed	in	vitro	is	analogous	to	that	generating	the	toxicity	observed	in	vivo.	Inhibition	
of	 primary	 nucleation	 is	 the	 dominant	 action	 of	 DNAJB6,	 although	DNAJB6	was	 also	 found	 to	
delay	secondary	nucleation	(Fig	1)	but	to	a	much	smaller	extent.		
	
The	S/T-rich	region	in	DNAJB6	and	role	of	hydroxyl	side	chains.	
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The	S/T	rich	stretch	is	unique	for	DNAJB6	and	DNAJB8	within	the	DNAJ	family	and	its	deletion	has	
been	 found	 to	 result	 in	 a	 loss	 of	 function	 in	 aggregation	 inhibition	 (Hageman	 et	 al.,	 2010).	
However,	since	deletion	of	the	entire	S/T-rich	region	also	affected	DNAJB6	structure,	oligomeric	
conformation	 and	 HDAC	 binding,	 it	 was	 unclear	 as	 to	whether	 or	 not	 this	 stretch	was	 in	 fact	
directly	involved	in	suppression	of	polyQ	aggregation.	The	results	described	here	show	that	S/T-
to-A	 substitution	 does	 not	 affect	 the	 secondary	 structure	 and	 oligomeric	 conformation	 of	
DNAJB6,	 and	 demonstrate	 that	 the	 extremely	 efficient	 inhibition	 by	 DNAJB6	 of	 primary	
nucleation	 is	 totally	dependent	on	 this	 region	of	DNAJB6,	and	of	 the	array	of	18	hydroxyl	 side	
chains	 that	 is	 exposed	 asymmetrically	 on	one	 side	 of	 the	DNAJB6	monomer	 structure	 (Fig.	 1).	
This	 array	 provides	 this	 chaperone	 with	 multivalent	 hydrogen	 bonding	 capacity	 that	 can	 be	
presumed	to	be	the	key	factor	that	enables	it	to	directly	bind	to	and	suppress	amyloid	formation	
by	polyQ	proteins	(Figs.	1,	3-5).	Moreover,	this	is	the	first	identified	functional	substrate	binding	
domain	in	a	human	DNAJ	protein.		
	
Comparison	of	DNAJB6	functionality	with	that	of	other	heat	shock	proteins.	
Our	data	also	provide	an	explanation	 for	 the	 findings	 that	DNAJB6	 (and	DNAJB8)	are	 the	most	
potent	 suppressors	 of	 polyQ	 aggregation	 within	 the	 human	 chaperonome	 (Hageman	 et	 al.,	
2010).	The	protective	effects	of	DNAJB6	in	the	aggressive	R6/2	polyQ	mouse	model	(Figs.	6,	7)	is	
the	 largest	 reported	 protection	 so	 far	 for	 any	 study	 involving	 the	 over-expression	 of	 a	 single	
human	 chaperone.	 Indeed,	 HSPA1A	 (Hsp70)	 and	 HSPB1	 (Hsp27)	 have	 been	 found	 to	 be	
ineffective	 in	 this	model	 (Hansson	et	 al.,	 2003;	Hay	et	 al.,	 2004;	 Zourlidou	et	 al.,	 2007),	whilst	
DNAJB2,	 a	 DNAJ	 protein	 that	 is	 related	 to	 DNAJB6	 but	 lacks	 the	 S/T	 stretch,	 leads	 to	modest	
effects	on	disease	onset	(Labbadia	et	al.,	2012).	The	high	potency	of	DNAJB6	can	be	attributed	to	
its	 direct	 interaction	 with	 the	 amyloid	 forming	 polyQ	 expansions,	 inhibiting	 primary	 and	 also	
secondary	nucleation	(Fig.	1).	Other	chaperones	like	HSPA1A	(Hsp70)	or	DNAJB1	(Hsp40)	cannot,	
however,	 act	 in	 this	 way	 but	 may	 interact	 with	 polyQ	 inclusions	 after	 they	 are	 formed,	 for	
example	by	binding	 to	exposed	hydrophobic	groups	of	 the	aggregated	polyQ	proteins.	 Indeed,	
Hsp70,	 DNAJB1	 and	 several	 small	 HSPs	 are	 often	 found	 to	 decorate	 the	 outer	 rim	 of	 polyQ	
aggregates	(Gillis	et	al.,	2013),	where	they	may	function	to	inhibit	aggregate	growth	(elongation),	
for	example	to	promote	the	disposal	of	aggregates	by	autophagy,	as	shown	for	some	small	HSP	
chaperones	(Carra	et	al.,	2008;	Crippa	et	al.,	2010),	or	to	recover	sequestered	proteins	from	the	
polyQ	aggregates	for	refolding	or	proteasomal	degradation,	as	suggested	for	the	canonical	Hsp70	
system	(Bailey	et	al.,	2002;	Howarth	et	al.,	2009).	Such	chaperone	effects	would	 lead	to	no,	or	
only	minor,	reductions	in	the	extent	of	aggregation,	but	could	alleviate	some	of	the	down-stream	
consequences	of	polyQ	protein	aggregation	and	lead	to	a	transient	delay	of	symptoms	(Chan	et	
al.,	2000;	Warrick	et	al.,	1999),	although	this	effect	appears	insufficient	for	long-term	protection	
in	the	above-mentioned	mice	models.		
The	 finding	 that,	 in	 cells,	 DNAJB6	 and	 DNAJB8	 not	 only	 delay	 aggregation	 of	 polyQ	
containing	 huntingtin,	 but	 also	 of	 polyQ	 containing	 ataxin-3	 and	 the	 androgen	 receptor	
(Hageman	et	al.,	 2010),	 further	 supports	 the	conclusion	 that	 its	action	must	 involve	 the	polyQ	
stretch	itself	in	a	context-independent,	generic	manner,	consistent	with	its	ability	to	chaperone	
pure	polyQ	peptides	 (this	 report,	Månsson	et	al.,	2014a).	For	 this	 to	happen,	 it	 is	 important	to	
note	that	the	polyQ	stretch	in	the	full-length	polyQ	proteins	usually	is	not	exposed	and	that	the	
full-length	polyQ	proteins	are	not	intrinsically	misfolded,	which	is	another	reason	why	canonical	
chaperones	 may	 not	 recognize	 them	 prior	 to	 aggregation,	 and	 thus	 are	 not	 very	 effective	 in	
suppressing	these	diseases.	In	line	with	this	conclusion,	expression	of	full	length	polyQ	proteins	
does	 not	 trigger	 the	 heat	 shock	 response	 (Hageman	 et	 al.,	 2010;	 Seidel	 et	 al.,	 2012)	 and	 the	
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steady	 state	 expression	 levels	 of	 the	 expanded	 and	 non-expanded	 alleles	 are	 identical	 in	 cells	
from	polyQ	patients	 (Koch	et	 al.,	 2011;	 Zijlstra	et	 al.,	 2010),	 strongly	 indicating	 that	 the	polyQ	
expansion	does	render	the	protein	a	target	for	accelerated	degradation	as	seen,	for	example,	for	
misfolded	 disease-associated	 proteins	 such	 as	 the	 mutational	 variants	 of	 SOD1	 that	 are	
responsible	for	ALS	(Crippa	et	al.,	2010),	or	some	of	the	CFTR	mutants	that	are	associated	with	
cystic	 fibrosis	 (Villella	 et	 al.,	 2013).	 For	 the	 polyQ	 expansion	 to	 become	 exposed	 and	 initiate	
aggregation,	 several	 lines	 of	 evidence	 have	 revealed	 that	 the	 full	 length	 proteins	 have	 to	 be	
shortened,	either	by	protease	cleavage	(Graham	et	al.,	2006)	or	via	alternative	splicing	(Ramani	
et	 al.,	 2015;	 Sathasivam	 et	 al.,	 2013),	 or	 need	 to	 undergo	 conformational	 changes	 such	 that	
flanking	sequences	open	up	or	align	the	polyQ	stretch	for	β-hairpin-mediated	nucleation	(Hoop	
et	 al.,	 2014;	 Kar	 et	 al.,	 2013;	 Orr	 et	 al.,	 2010;	 Sivanandam	 et	 al.,	 2011).	 In	 addition,	 or	
alternatively,	polyQ	peptides	can	be	generated	upon	proteasomal	degradation	that,	in	a	polyQ-
length	dependent	manner,	may	aggregate	and	act	as	seeds	for	fibril	formation	(Gillis	et	al.,	2013;	
Raspe	 et	 al.,	 2009).	 At	 this	 stage	 DNAJB6,	 but	 not	 canonical	 chaperones,	 would	 be	 able	 to	
prevent	such	seeds	from	being	formed.	
Whereas	prevention	of	polyQ	aggregation	by	DNAJB6	has	previously	been	suggested	to	be	
independent	of	 its	ability	 to	work	within	 the	context	of	 the	Hsp70	machinery	 (Hageman	et	al.,	
2010),	our	current	data	demonstrate	that	this	idea	has	to	be	revised.	This	activity	is	not	yet	fully	
saturated	under	 the	conditions	used	previously	 (Hageman	et	al.,	2010),	a	situation	 that	 results	
from	the	extremely	efficient	substrate-binding	capacity	of	DNAJB6	at	sub	stoichiometric	 ratios.	
Our	 current	 data	 with	 the	 QPD-M2	 double	 mutant	 of	 DNAJB6	 (Fig.	 5)	 demonstrate	 that	 the	
additional	QPD	mutation	 in	 the	M2	mutational	 variant	of	DNAJB6,	 already	 compromised	 in	 its	
anti-aggregation	 activity	 (Fig.	 1),	 almost	 completely	 reduced	 its	 ability	 to	 prevent	 polyQ	
aggregation	in	cells.	This	double	mutant	form	of	DNAJB6	required	Hsp70	for	efficient	functioning,	
showing	that	DNAJB6	indeed	is	a	DNAJ	protein	with	capability	to	interact	with	Hsp70.	Moreover,	
these	data	suggest	that	DNAJB6	acts	to	keep	polyQ-containing	stretches	in	a	form	competent	for	
degradation	 via	 Hsp70,	 at	 the	 same	 time	 releasing	 DNAJB6	 for	 preventing	 new	 primary	
nucleation	reactions.	The	Hsp70-independent	ability	of	DNAJB6	to	delay	polyQ	aggregation	in	a	
cell	 free	system	(Månsson	et	al.,	2014a)	 is	not	 inconsistent	with	such	a	model,	as	 the	released	
seeds	would	not	be	degraded	and	thus	would	not	change	the	substrate-to-chaperone	ratio.	How	
the	 substrates	 released	 from	 DNAJB6	 by	 HSP70	 are	 processed	 (e.g.	 by	 hand-over	 to	 either	
proteases,	 peptidases	 or	 autophagy)	 is	 currently	 under	 investigation,	 but	 the	 association	 of	
DNAJB6	with	HDACs	(Hageman	et	al.,	2010)	suggests	that	autophagy	may	play	a	significant	role.	
	
Physiological	functions	of	DNAJB6.	
DNAJB6	 is	expressed	ubiquitously,	not	 just	 in	 the	brain,	and	DNAJB6	orthologs	are	 found	 in	all	
metazoans	analyzed	so	 far	 (Hageman	et	al.,	2010).	Yet,	 its	precise	 function	under	physiological	
conditions	remains	to	be	elucidated.	Besides	playing	a	potential	role	in	suppressing	unwanted	or	
uncontrolled	amyloid	formation,	some	data	suggest	that	DNAJB6	is	important	during	(excessive)	
protein	 degradation;	 for	 example,	 DNAJB6	 has	 been	 suggested	 to	 play	 a	 role	 during	 keratin	
degradation	(Izawa	et	al.,	2000;	Watson	et	al.,	2007),	which	may	explain	why	DNAJB6	knockout	
mutant	mice	die	due	to	 failures	of	chorioallantoic	 fusion	 (Hunter	et	al.,	1999).	 In	 line	with	 this	
view,	expression	network	analysis	 (Fig.	 S12)	 reveals	 that	DNA	expression	 is	 strongly	associated	
with	 catabolic	 processes.	 One	 speculative	 possibility	 is	 that	 DNAJB6	may	 play	 a	more	 general	
action	 in	 preventing	 amyloid	 formation	 by	 parts	 of	 proteins,	 shorter	 than	 full	 length	 proteins,	
that	are	generated	during	such	catabolic	proteolytic	events.	In	line	with	this	idea,	it	is	important	
to	note	that	mutations	in	DNAJB6	that	cause	a	dominant	heritable	form	of	limb-girdle	muscular	
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dystrophy	(Harms	et	al.,	2012;	Sarparanta	et	al.,	2012)	are	associated	with	congophilic	inclusions	
and	vacuolar	changes	that	are	specific	to	amyloid	formation	in	muscle	biopsies	(Suarez-Cedeno	
et	al.,	2014),	 supporting	 the	proposal	 that	 it	has	an	 important	anti-aggregation	role	 in	muscles	
under	physiological	conditions.	
	 Specific	overexpression	of	DNAJB6	 in	 the	brain	has	not	been	 found	 to	have	deleterious	
phenotypic	 effects,	 at	 least	 in	 the	 mouse	 model	 used	 here,	 suggesting	 that	 it	 could	 be	 a	
potentially	 safe	 therapeutic	 target	 in	polyQ	diseases.	 Furthermore,	 in	 line	with	 the	absence	of	
effects	on	the	general	chaperone	network	 in	the	brain	(Figs.	S8,	9),	 the	tissue-specific	effect	of	
DNAJB6	 implies	 that	 its	upregulation	does	not	 lead	to	cell-non-autonomous	effects	of	 the	type	
that	have	been	suggested	to	occur,	 for	example,	with	 the	HSR-regulator	DNAJB1	 (Popiel	et	al.,	
2012).	This	observation,	and	the	fact	that	DNAJB6	does	not	require	a	simultaneous	upregulation	
of	 Hsp70	 for	 its	 chaperone	 activity,	 is	 likely	 to	 be	 a	major	 advantage	 because	 altering	 Hsp70	
expression	levels	has	been	associated	with	an	increased	risk	of	malignancies	(Dai	et	al.,	2007).	In	
addition,	 DNAJB6	 is	 active	 in	 cells	with	 a	 compromised	 heat	 shock	 response	 (Hageman	 et	 al.,	
2010),	which	suggests	that	it	may	remain	active	in	aging	neuronal	cells	in	which	this	HSR	may	be	
attenuated	(Akerfelt	et	al.,	2010)	
The	ability	of	DNAJB6	to	inhibit	the	primary	nucleation	step	in	the	aggregation	of	polyQ	
peptides,	 observed	 in	 the	present	 study,	 appears	 to	be	unique	 amongst	 the	DNAJ	 chaperones	
investigated	so	far.	DNAJB6	might,	therefore,	also	play	an	important	role	in	the	context	of	other	
human	 disorders,	 in	 addition	 to	 those	 associated	 with	 polyQ	 aggregation,	 where	 amyloid	
formation	is	an	important	factor.	Such	disorders	include	Alzheimer’s	disease,	the	most	common	
cause	of	age-related	dementia,	that	is	initiated	by	Aβ	peptides	(Knowles	et	al.,	2014),	and	type	2	
diabetes,	 in	which	 the	cascade	 initiating	aggregation	 involves	 IAPP	peptides,	a	major	 secretory	
product	of	β-cells	(Westermark	et	al.,	2011).	Indeed,	we	have	recently	found	that	DNAJB6	is	able	
to	 interact	 with,	 and	 delay	 fibril	 formation	 by,	 the	 Aβ42	 peptide	 (Månsson	 et	 al.,	 2014b). In	
conclusion,	molecular	species	that	are	able	to	 interfere	with	protein	aggregation	are	of	utmost	
importance	 for	 understanding	 the	 role	 of	 amyloid	 formation	 in	 biology	 and	 disease.	 Further	
insights	into	the	mechanism	by	which	DNAJB6	inhibits	this	process	will	help	to	understand	both	
the	nature	of	 the	aggregation	process	 itself	 and	of	 its	 inhibition,	and	may	 thereby	 serve	as	an	
important	 lead	 for	 future	 therapeutic	 developments	 directed	 against	 this	 family	 of	 highly	
debilitating	amyloid	diseases.		
	
Experimental Procedures 
 
Recombinant	proteins	and	peptides.		
DNAJB6	protein.	The	 residue	numbering	 refers	 to	 the	 amino	 acid	 sequence	of	 human	DNAJB6	
isoform	b	(UniProt	KB	accession	number	O75190-2).	DNAJB6	was	recombinantly	expressed	with	
an	N-terminal	tag	containing	six	histidines	and	a	tobacco	etch	virus	(TEV)	protease	cleavage	site	
(tag	 sequence	MHHHHHHGKPIPNPLLGLDSTENLYFQGIDPFT).	 After	 TEV-cleavage	 and	 removal	 of	
the	 His-tag,	 the	 amino	 acid	 residues	 GIDPFT	 remain	 at	 the	 N-terminal	 end	 of	 the	 DNAJB6	
protein).	 Substitution	 mutants	 were	 generated	 with	 6,	 13	 or	 18	 S/T-to-A	 substitutions	 in	 the	
conserved	S/T-rich	region	and	designated	M1,	M2,	and	M3	and	one	deletion	mutant	(Δ132-183),	
with	 21	 S/T	 residues	 and	 in	 total	 35	 residues	 deleted,	 and	 designated	M4.	 Expression	 of	 the	
DNAJB6	 protein	 and	 its	 mutational	 variants	 was	 performed	 at	 the	 Lund	 Protein	 Production	
Platform,	 Lund	 University,	 Sweden	 (http://www.lu.se/lp3).	 Purification	 and	 characterization	 of	
the	 proteins	 by	 native	 electrophoresis	 and	 CD	 spectroscopy	 was	 performed	 as	 previously	
described	 (Månsson	 et	 al.,	 2014a,	 2014b).	 Size	 exclusion	 chromatography	was	 performed	 at	 a	
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flow	rate	of	0.5	ml/min	on	a	Superdex	200	Increase	10/300	GL	column	(GE	Healthcare,	Uppsala,	
Sweden)	 equilibrated	 with	 20	 mM	 sodium	 phosphate	 buffer	 pH	 8	 and	 150	 mM	 NaCl.	 	 The	
preparation	of	 the	polyQ	peptide	used	here	 for	 in	 vitro	 studies	has	been	described	previously	
(Månsson	 et	 al.,	 2014a)	 and	 has	 the	 sequence	 GAMKSFQ45F	 (Q45)	 attached	 to	 the	 maltose	
binding	protein	via	a	TEV	protease	cleavage	site	(referred	to	as	MBP-TEV-Q45),	which	permits	a	
controlled	initiation	of	the	fibril	formation	reaction	following	addition	of	TEV	protease.		
PolyQ	peptide.	The	polyQ	peptide	was	recombinantly	expressed	as	a	fusion	with	maltose	binding	
protein	with	an	N-terminal	tag	containing	six	histidines	and	a	tobacco	etch	virus	(TEV)	protease	
cleavage	site	(MBP-TEV-Q45),	in	E.	coli	strain	BL21(DE3)	(Stratagene,	Santa	Clara,	CA,	USA).	The	
protein	lysate	was	loaded	onto	a	10	ml	bed	volume	Talon	metal	affinity	resin	column	(Clontech,	
Saint-Germain-en-Laye,	 France),	 equilibrated	 in	 20	mM	Tris–HCl,	 pH	 7.5;	 100	mM	KCl;	 20	mM	
imidazole;	10	%	glycerol	and	1	mM	DTT,	and	an	imidazole	gradient	(20–500	mM)	was	applied	and	
the	His-tagged	MBP-TEV-Q45	was	eluted	at	200	mM	imidazole,	and	then	loaded	on	the	UnoQ6	
column	 (BioRad,	Marnes-la-Coquette,	 France)	 equilibrated	 in	 20	mM	Tris–HCl,	 pH	 7.5;	 20	mM	
KCl;	and	1	mM	DTT.	The	column	was	washed	with	five	bed	volumes	of	the	equilibration	buffer,	
and	then	a	KCl	gradient	(20–500	mM)	was	applied,	and	the	His-tagged	MBP-TEV-Q45	eluted	at	
200	mM	KCl.	The	protein	concentration	was	determined	from	its	absorbance	at	280	nm	using	an	
extinction	coefficient	of	67840	M-1	cm-1.	This	fusion	protein	was	stored	at	-80°C	in	aliquots	that	
were	thawed	just	before	use,	and	polyQ	peptides	were	released	by	addition	of	TEV	protease.	
	
DNAJB6	binding	to	polyQ	evaluated	by	filter	trap	assay	After	assays	for	DNAJB6	suppression	of	
polyQ	aggregation,	the	amount	of	DNAJB6,	or	its	mutational	variants,	bound	to	the	polyQ	fibrils	
were	evaluated	with	a	filter	trap	assay.	End	products	in	the	wells	after	the	fibrillation	assays	were	
mixed	1:1	(volume)	with	2	%	SDS	in	PBS	(137	mM	NaCl,	2.7	mM	KCl,	10	mM	Na2HPO4	and	1,8	
mM	 KH2PO4)	 and	 transferred	 to	 a	 cellulose	 acetate	 membrane	 filter	 (pore	 size	 0.2	 μm,	 GE	
Healthcare,	Uppsala,	Sweden)	on	a	suction	device.	The	membrane	 filter	was	washed,	 to	 retain	
only	polyQ	in	fibril	 form,	twice	with	PBS	supplemented	with	1	%	SDS	and	once	with	PBS	alone,	
after	which	it	was	blocked	by	incubation	with	blocking	buffer	(LI-COR,	Cambridge,	UK)	for	1h	at	
RT,	 then	 incubated	 with	 blocking	 buffer	 containing	 1:1000	 polyclonal	 rabbit	 anti	 DNAJB6	
(Innovagen,	 Lund,	 Sweden)	 antibodies	 for	 1h	 at	 RT	 after	 which	 it	 was	 washed	 with	 PBS	
supplemented	with	0.1	%	Tween-20	(PBS-T)	twice	for	5	min.	Subsequently	the	membrane	filter	
was	incubated	with	IRDye	800CW	goat	anti	rabbit	(LI-COR,	Cambridge,	UK)	in	blocking	buffer	for	
1h	at	RT	in	the	dark	before	being	washed	again,	dried	in	the	dark	and	imaged	at	800	nm	using	an	
Odyssey	CLx	IR	imaging	system	(LI-COR).	IR	intensity	of	the	reactions	with	chaperone	was	divided	
by	 the	 intensity	 of	 control	 reactions	 using	 Image	 Studio	 for	 Odyssey	 CLx	 and	 Classic	 (LI-COR),	
which	was	also	used	to	generate	images.	
	
	
Assay	 for	 DNAJB6	 suppression	 of	 polyQ	 aggregation.	 PolyQ	 fibril	 formation	was	 analyzed	 by	
Thioflavin	T	(ThT)	fluorescence;	15	μM	MBP-TEV-Q45	was	mixed	with	DNAJB6	or	its	mutational	
variants	 in	 two	 distinct	 molar	 ratios	 (1:0.1	 and	 1:0.01)	 of	 MBP-TEV-Q45	 to	 DNAJB6	 and	 its	
mutational	 variants	 in	 buffer	 (55.9	 mM	 NaPB,	 143.5	 mM	 NaCl	 and	 1.35	 mM	 KCl,	 pH	 8.0),	
supplemented	with	10	μM	ThT	 for	detection	of	 fibril	 formation	and	1.5	ng/ml	TEV	protease	to	
initiate	 the	 reaction.	 Samples	 were	 prepared	 on	 ice	 and	 80	 µl	 aliquots	 were	 transferred	 to	
microplate	wells	(Corning®	96	well	plates,	half-area	black/clear	bottom	polystyrene,	nonbinding	
surface,	 Corning	 Incorporated	 Life	 Sciences,	 Acton,	 USA)	 in	 triplicate.	 ThT	 fluorescence	 was	
measured	every	120,	 150	or	300	 s	using	quiescent	 conditions	 at	 37°C	using	a	 Fluostar	Optima	
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platereader	(BMG	Labtech,	Offenburg,	Germany)	with	excitation	at	440	nm	and	emission	at	480	
nm.	The	fluorescence	data	were	normalized,	the	lowest	value	in	the	dataset	being	set	to	0	and	
the	highest	to	1	for	each	reaction	separately.	The	halftimes	(t½)	and	values	of	the	slopes	were	
determined	by	fitting	non-linear	sigmoidal	dose-response	curves	to	the	normalized	data.	Within	
each	experiment	these	values	were	divided	by	the	average	values	of	three	replicates	of	reactions	
without	the	chaperone.	These	ratios	were	averaged	for	three	independent	experiments	and	the	
standard	error	of	mean	(SEM)	was	calculated.	For	analysis	of	aggregation	kinetics,	 the	reaction	
profiles	were	 fitted	by	 integrated	 rate	 laws	 for	 nucleation	 and	 growth	 as	 previously	 described	
(Arosio	et	al.,	2014;	Cohen	et	al.,	2011a,	2011b),	considering	rate	constants	in	the	absence	and	
presence	of	different	concentrations	of	DNAJB6	and	the	mutational	variants,	where	kn,	k+	and	k2	
are	 the	 primary	 nucleation,	 fibril	 elongation	 and	 secondary	 nucleation	 rate	 constants,	
respectively.		
	
Kinetic	analysis	of	polyQ	aggregation	in	vitro.	To	connect	the	macroscopic	measurements	with	
the	 details	 of	 the	 microscopic	 mechanism	 underlying	 the	 inhibition	 of	 polyQ	 	 aggregation	 by	
DNAJB6,	 we	 applied	 a	 recently	 developed	 chemical	 kinetics	 platform.	 To	 this	 effect,	 the	
experimental	 kinetic	 data	 in	 vitro	 were	 analysed	 by	 using	 a	 kinetic	 model	 that	 considers	 the	
processes	of	primary	nucleation,	elongation	and	secondary	nucleation.	The	time	evolution	of	the	
total	 fibril	 mass	 M(t)	 in	 the	 presence	 of	 both	 primary	 and	 secondary	 nucleation	 events	 is	
described	by	the	following	integrated	rate	law	(Cohen	et	al.,	2011a,	2011b):		
	
	{1},		
	
where	 the	 kinetic	 parameters	 B±,	 C±,	 and	 κ	 are	 functions	 of	 the	 two	 combinations	 of	 the	
microscopic	 rate	 constants	 k+k2	 and	 k+kn,	 where	 kn,	 k+	 and	 k2	 are	 the	 primary	 nucleation,	
elongation	and	 secondary	nucleation	 rate	 constants,	 respectively.	 The	microscopic	aggregation	
mechanism	of	the	Q45	peptide	 in	the	absence	of	the	chaperone	was	 identified	by	applying	Eq.	
{1}	to	globally	fit	the	reaction	profiles	at	different	concentrations	of	Q45.	The	experimental	data	
were	 taken	 from	 (Månsson	 et	 al.,	 2014a)	 and	 the	 reaction	 orders	 of	 primary	 and	 secondary	
nucleation	 were	 fixed	 as	 2	 based	 on	 the	 scaling	 of	 the	 halftimes	 with	 initial	 peptide	
concentrations.	This	global	analysis	 indicated	that	the	aggregation	of	the	polyQ	peptides	under	
the	 conditions	 explored	 in	 the	 present	 study	 is	 dominated	 by	 secondary	 nucleation,	 although	
primary	 nucleation	 occurs	 to	 generate	 the	 initial	 species	 that	 subsequently	 proliferate	 by	
secondary	 nucleation.	 The	 microscopic	 steps	 that	 are	 inhibited	 by	 DNAJB6	 were	 analysed	 by	
applying	Eq.	{1}	to	describe	the	macroscopic	profiles	of	the	reactions	performed	in	the	presence	
of	DNAJB6.	The	microscopic	reaction	steps	were	identified	by	comparing	the	set	of	microscopic	
rate	constants	k+k2	and	k+kn	required	to	describe	the	time	evolution	of	the	fibril	formation	in	the	
absence	and	presence	of	DNAJB6.		
	
Structural	model	of	DNAJB6.	To	generate	structural	models	the	DNAJB6	sequence	was	uploaded	
to	 the	Robetta	 server	 (http://robetta.bakerlab.org,	 (Song	et	 al.,	 2013).	 Intra-	 and	 inter-domain	
crosslinks	 identified	by	CXMS	were	used	as	distance	 constraints	 to	 filter	 the	 structural	models	
and	 select	 that	with	 the	 best	 fit.	 Crosslinking	 experiments	were	 performed	 in	 20	mM	 sodium	
phosphate	 buffer	 pH	 8.0	 and	 150	 mM	 NaCl.	 The	 crosslinking	 reagents	 DSSG	
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(disulfosuccinimidylglutarate,	 also	 abbreviated	 as	 BS2G	 for	 bis[sulfosuccinimidyl]glutarate)	 and	
BS3	 (bis[sulfosuccinimidyl]suberate),	 are	 amine-reactive,	 water	 soluble,	 homobifunctional	
protein	 crosslinkers	 yielding	 7.7	 Å	 and	 11.4	 Å	 long	 spacer	 arms	 between	 lysine	 residues,	 and	
were	 purchased	 from	 Creative	 Molecules	 Inc.	 (Victoria,	 Canada).	 The	 DNAJB6	 protein	
concentration	 was	 1	 mg/ml.	 The	 crosslinking	 agents	 were	 dissolved	 in	 distilled	 water	 to	 a	
concentration	 of	 30	 mM	 immediately	 before	 use,	 and	 added	 to	 a	 40	 times	 molar	 excess	 of	
crosslinker	to	protein.	Sample	aliquots	were	incubated	with	non-isotopically	coded	or	isotopically	
coded	crosslinkers	at	37	°C.	After	15	min,	the	crosslinking	reaction	was	quenched	by	an	excess	of	
primary	amine	by	adding	1	M	Tris-(hydroxymethyl)-aminomethane	to	a	final	concentration	of	20	
mM.	 The	 samples	 were	 then	 subjected	 to	 denaturing	 gel	 electrophoresis	 performed	 using	
precast	4–12	%	NuPAGE®	Bis–Tris	Gels	(Life	Technologies	Europe	BV,	Stockholm,	Sweden)	in	MES	
buffer	 according	 to	 the	 manufacturer’s	 instructions.	 Samples	 were	 diluted	 with	 LDS	 sample	
buffer	(4×)	(Life	Technologies	Europe	BV,	Stockholm,	Sweden)	and	solubilized	for	10	min	at	95	°C.	
Gels	were	stained	with	Coomassie	Brilliant	Blue	G-250	according	to	the	Quick-stain	colloidal	CBB	
protocol	 (Lawrence	and	Besir,	2009).	The	band	corresponding	to	crosslinked	DNAJB6	monomer	
was	 than	 excised	 and	 subjected	 to	 in-gel	 digestion	 (ratio	 1:50	 protease	 to	 protein)	 with	 a	
combination	of	trypsin	and	chymotrypsin	(Promega,	Madison,	WI,	USA)	at	37	°C.	Samples	were	
acidified	by	adding	2	μl	10	%	trifluoroacetic	acid	(TFA).	The	resulting	peptides	were	subjected	to	
reversed	phase	nano-LC	prior	to	mass	spectrometric	analyses	 in	a	LTQ-Orbitrap	Velos	Pro	mass	
spectrometer	(Thermo	Fisher	Scientific,Hägersten,	Sweden)	equipped	with	a	nanoEasy	spray	ion	
source	 (Proxeon	 Biosystems,	 Odense,	 Denmark).	 The	 chromatographic	 separation	 was	
performed	at	400C	on	a	15	cm	(75	μm	i.d.)	EASY-Spray	column	packed	with	3	μm	resin	(Proxeon	
Biosystems,	 Odense,	 Denmark).	 The	 nanoHPLC	 intelligent	 flow	 control	 gradient	 was	 5–20%	
solvent	B	(0.1%	(v/v)	FA,	100%	(v/v)	acetonitrile	in	water)	in	solvent	A	(0.1%	(v/v)	FA	in	water)	for	
60	min,	and	then	20%-40%	for	30	min	followed	with	an	increase	to	90%	for	5	min.	A	flow	rate	of	
300	 nl/min	 was	 used	 through	 the	 whole	 gradient.	 An	 MS	 scan	 (usually	 350–2000	 m/z)	 was	
recorded	 in	 the	 Orbitrap	 mass	 analyzer	 set	 at	 a	 resolution	 of	 60,000	 at	 400	 m/z,	 1	 ×	 106	
automatic	gain	control	target	and	500	ms	maximum	ion	injection	time.	The	MS	was	followed	by	
data-dependent	collision-induced	dissociation	MS/MS	scans	on	the	8	or	10	most	intense	multiple	
charged	ions	at	15,000	signal	threshold,	30,000	automatic	gain	control	target,	300	ms	maximum	
ion	 injection	 time,	 2.5	 m/z	 isolation	 width,	 10	 ms	 activation	 time	 at	 35	 normalized	 collision	
energy	 and	 dynamic	 exclusion,	 for	 30	 or	 60	 s,	 with	 a	 repeat	 count	 of	 1.	 The	 general	 mass	
spectrometric	conditions	were	as	follows:	spray	voltage,	2.0	kV;	no	sheath	or	auxiliary	gas	flow;	
S-lens	60%;	 ion	transfer	tube	temperature,	275	°C.	Raw	data	were	converted	to	mgf-format	by	
Mascot	Distiller	(version	2.3)	and	further	filtered	to	retain	only	the	top	125	most	intense	peaks	
per	 scan	with	 the	 software	MassAI	 (version	August	 2014;	http://www.massai.dk;	 ((Peng	et	 al.,	
2014;	 Rasmussen	 et	 al.,	 2011).	 The	 identification	 of	 crosslinks	 was	 made	 with	 the	 following	
search	 settings:	 Fragmentation	 mode:	 CID,	 10	 ppm	 MS	 accuracy,	 0.04	 Da	 MS/MS	 accuracy,	
trypsin	 combined	 with	 chymotrypsin	 as	 enzyme,	 4	 allowed	 missed	 cleavages,	 Variable	
modifications	K	(BS3-H20	(x-linker)),	K	(BS3-d12-H20	(x-linker)),	K	(BS2G-H20	(x-linker)),	K	(BS2G-
d6-H20	(x-linker)),	Crosslinkers	BS3	(d0/d12)	or	BS2G	(d0/d6),	Also	xlink	modified	peptides.	The	
sequences	used	in	data	analysis	refer	to	the	amino	acid	sequence	for	DNAJB6	isoform	B	(UniProt	
KB	accession	number	O75190-2).	
	
Cell	culture	and	transient	transfections.	Human	embryonic	kidney	cells	 (HEK293)	and	neuronal	
cells	 (NG108,	 fusion	of	neuroblastoma	and	glioma	clones)	were	cultured	according	to	standard	
protocols	in	DMEM	(Invitrogen,	41966-052)	supplemented	with	10%	fetal	bovine	serum	(Greiner	
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Bio-One,	758093)	and	penicillin/streptomycin	(Invitrogen,	15140-163).	Differentiation	 in	NG108	
cells	was	 induced	using	1%	NECA	 (Sigma)	 and	0.1%	 IBMX	 (Sigma).	 Cells	were	 transfected	with	
exon-1	 Htt-Q119-eYFP,	 pcDNA5/FRT/TO	 DNAJB6-V5	 48	 h	 post	 differentiation,	 using	 the	
Lipofectamine	2000	reagent	(Invitrogen,	CA,	USA)	according	to	the	manufacturer’s	 instructions.	
Transfection	rates	were	~10%	for	NG108	cells	and	>	70%	for	HEK293	cells;	for	transfections	with	
multiple	constructs,	co-expression	was	always	~	90%.	 Immunocytochemistry	was	performed	as	
described	 earlier	 (Hageman	 et	 al.,	 2010).	 For	 immune-staining,	 differentiated	 cells	 were	
additionally	stained	for	βIII-tubulin	to	visualize	neurites.		
	
Cell	 and	 tissue	 extracts	 and	 sample	 preparation	 for	 western	 blotting.	 HEK293	 cells	 were	
prepared	and	treated	as	described	previously	(Hageman	et	al.,	2010).	For	extracellular	addition	
of	 polyQ	 peptide	 in	 aggregated	 and	 fibrillar	 forms	 polyQ	 peptide,	 the	 peptides	 K2Q30K2	 and		
K2Q45K2	were	generated	as	described	before	(Ren	et	al.,	2009).	The	peptides	were	added	to	the	
culture	medium	at	 a	 concentration	of	 1	µM	one	day	 after	 transfection	with	 the	plasmids	Htt-
Q23-GFP	or	Htt-Q47-GFP	 and	DNAJB6-V5.	 After	 the	 indicated	 time	 following	 peptide	 addition,	
the	cells	were	washed	with	PBS	and	scraped	in	FTA-buffer	(10	mM	Tris-Cl	pH8.0,	150	mM	NaCl)	+	
2%	 SDS	 and	 sonicated.	 Seeding	 of	 intracellular	 expressed	 Htt-Q23-GFP	 or	 Htt-Q74-GFP	
aggregation	in	HEK293	cells	was	induced	by	addition	of	extracellular	preformed	Q45	fibrils	(1µM)	
one	 day	 after	 transfection	 with	 the	 plasmids	 encoding	 Htt-Q23-GFP	 or	 Htt-Q74-GFP	 with	 or	
without	 plasmids	 encoding	 DNAJB6-V5.	 Preformed	 Q45	 fibrils	 were	 obtained	 by	 incubating	
soluble	Q45	 (40	µM)	 in	20	mM	HEPES,	pH	7.5;	150	mM	NaCl	and	10%	glycerol,	at	37°C	without	
shaking.	Full	assembly	into	fibrils	was	achieved	within	5h	as	assessed	by	SDS-PAGE	analysis	and	
electron	 microscopy.	 To	 reduce	 fibrils	 length	 heterogeneity	 and	 bundling,	 preassembled	 Q45	
fibrils	were	sonicated	for	20	min	on	ice	in	2-mL	Eppendorf	tubes	in	a	VialTweeter	powered	by	an	
ultrasonic	processor	UIS250v	(250	watts,	2.4	kHz;	Hielscher	Ultrasonic,	Teltow,	Germany)	set	at	
75%	 amplitude,	 0.5	 s	 pulses.	 Transmission	 electron	micrographs	 of	 fibrillar	Q45	 adsorbed	 onto	
carbon-coated	200	mesh	grids	and	negatively	 stained	with	1%	uranyl	acetate	 in	distilled	water	
for	 1	 min	 were	 acquired	 using	 JEOL	 1400	 transmission	 electron	 microscope	 operated	 at	 an	
excitation	 voltage	 of	 80kV	 and	 equipped	with	 a	 Gatan	Orius	 CDD	 Camera	 (Gatan)	 (Ren	 et	 al.,	
2009).	
Filter	trap	samples	were	prepared	as	described	before	(Hageman	et	al.,	2010).	For	mouse	tissue	
extracts	 and	 aggregate	 detection,	 the	 tissues	were	 snap	 frozen	 in	 liquid	 nitrogen	 immediately	
after	 dissection	 and	 homogenized	 (with	 a	 pellet	 pestle	 for	 brain	 tissue	 and	 a	 bead	 beater	 for	
muscle	tissue)	in	RIPA	buffer	with	NaCl	(150	mM),	igepal	cholate	(1%),	deoxycholate	(0.5%),	SDS	
(0.01%)	and	Tris-HCl	 (50	mM).	A	protease	 inhibitor	 cocktail,	 0.1	M	PMSF	and	0.5	M	DTT	were	
added	fresh	to	the	solution.	Samples	were	sonicated	and	left	on	ice	for	20	min	to	ensure	proper	
lysis	of	the	cells	and	release	of	proteins.	Samples	were	spun	at	high	speed	(13	000	rpm)	for	15	
min	and	the	pellets	were	discarded.	For	all	the	samples,	protein	content	was	determined	using	
the	 DC	 protein	 assay	 (BioRad,	 Veenendaal,	 Netherlands)	 and	 prepared	 in	 SDS-PAGE	 loading	
buffer	and	heated	for	5	min	at	100oC.	Equal	amounts	of	protein	(5	µg	for	NG108	cell	extracts	and	
50	 µg	 for	 tissue	 extract)	 were	 loaded	 on	 8%	 (Htt	 detection)	 and	 12.5%	 SDS-PAGE	 gels.	 The	
proteins	were	transferred	onto	nitrocellulose	membranes	and	probed	with	the	following	primary	
antibodies:	 anti-GFP	 (JL-8	 Clontech,	 Leusden,	 NL);	 anti-V5	 (Invitrogen,	 CA,	 USA);	 anti-DNAJB6	
(Abnova,	Walnut,	CA,	USA)	and	anti-GAPDH	(Fitzgerald	Industries	International,	Acton,	MA,	USA);	
anti-Htt	S829	(generated	in	the	Bates	laboratory,	London,	UK),	and	subsequently	incubated	with	
appropriate	 HRP-conjugated	 secondary	 antibodies	 (Amersham,	 Roosendaal,	 NL)	 and	 anti-goat	
HRP	(Santa	Cruz	Biotechnology,	Dallas,	Texas,	USA).	
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Confocal	microscopy.	Confocal	images	were	obtained	using	a	confocal	laser	scanning	microscope	
(Leica	 TCS	 SP8)	 with	 a	 63X/1.32	 oil	 objective.	 Images	 were	 processed	 using	 ImageJ	 software	
(http://rsb.info.nih.gov/ij/).	As	a	minor	manipulation,	a	background	correction	was	applied	to	all	
parts	of	the	image.		
	
FRAP	analysis.	Differentiated	NG108	cells	were	transfected	with	Htt-Q119-eYFP	with	or	without	
the	 mRFP-DNAJB6b	 construct	 and	 the	 V5-DNAJB6	 H/Q	 mutational	 variant;	 the	 plasmid	
description	can	be	found	in	(Hageman	et	al.,	2010).	12	h	post	transfection,	cells	were	observed	
and	images	were	collected	using	a	Zeiss	LSM780	Confocal	65	Laser	Scan	Microscope	63x/1.3Imm,	
equipped	with	incubation	chamber	with	CO2	and	temperature	control	(all	images	were	recorded	
at	37oC).	An	area	spanning	the	cytoplasm	was	recorded	using	minimum	laser	intensity	at	a	frame	
rate	of	1	per	s	(50	pre-bleach	recordings);	subsequently	the	strip	was	bleached	(one	iteration	at	
full	laser	intention)	and	recorded	for	10	s.	The	values	were	analysed	using	Zeiss	software	in	which	
they	were	normalized	to	the	pre-bleach	pulse;	only	the	post	bleach	curves	are	displayed	in	Figure	
3E.	
	
Immunoprecipitation	 protocols.	 For	 the	 polyQ-DNAJB6	 immunoprecipitation,	 HEK293T	 cells	
were	co-transfected	with	pcDNA5/FRT/TO	V5-DNAJB6b	WT	and	an	empty	pcDNA5/FRT/TO	mRFP	
vector	(0.9µg	each),	or	0.1	µg	of	Htt-Q119-YFP	and	0.9	µg	of	either	pcDNA5/FRT/TO	V5-DNAJB6b	
WT,	H31Q	or	M3	constructs.	For	 the	Hsp70-DNAJB6	 interaction	conditions	were	 identical,	with	
the	exception	that	the	Htt-Q119-YFP	vector	was	substituted	by	0.5	µg	of	GFP-HSPA1A	in	the	co-
transfections	with	the	DNAJB6	constructs.	24	hours	after	transfection,	cells	were	washed	twice	
with	PBS,	scraped	in	1ml	of	PBS,	and	centrifuged	for	5	minutes,	1.000	rpm	at	4oC.	Pellets	were	
resuspended	 in	 500	 µl	 PBS	 with	 the	 cross	 linker	 3,3ʹ-dithiodipropionic	 acid	 di(N-
hydroxysuccinimide	ester)	(1	mM	final	concentration,	Sigma-Aldrich)	and	incubated	on	ice	for	30	
min.	 The	 crosslinking	 reaction	 was	 stopped	 by	 addition	 of	 10	 µl	 of	 glycine	 (100	 mM)	 and	
incubation	on	ice	for	15	min.	After	centrifugation	for	5	min,	1.000	rpm	at	4oC,	cells	were	washed	
with	1	ml	PBS,	pelleted	again	and	flash-frozen	in	liquid	nitrogen.	Five	hundred	µl	of	 lysis	buffer	
(150	mM	NaCl,	50	mM	Tris-HCl	pH	8.0,	1.5	mM	MgCl2,	0.5%	NP-40	(v/w),	3%	glycerol	(v/w),	0.9	
mM	 DTT	 and	 complete	 EDTA-free	 protease	 inhibitor	 cocktail)	 were	 used	 to	 homogenize	 the	
pellets,	which	were	passed	7	 times	 through	a	26G	needle.	Cells	were	 spun	 for	15	min,	14.000	
rpm	at	4oC,	the	supernatant	fractions	were	transferred	to	new	tubes	and	30	µl	were	collected	
for	 input	 measurement	 before	 addition	 of	 25	 µl	 of	 GFP-Trap®	 magnetic	 beads	 (Chromotek,	
Planegg,	Germany).	Extracts	were	 incubated	at	4oC	for	2	h	under	gentle	agitation,	 followed	by	
one	wash	with	500	µl	of	lysis	buffer	without	DTT,	one	wash	with	500	µl	of	lysis	buffer	with	300	
mM	NaCl	 and	 four	washes	with	 lysis	 buffer	 (with	DTT	and	150	mM	NaCl)	 on	 a	magnetic	 rack.	
Beads	were	resuspended	in	25	µl	of	2X	Laemli	buffer	with	10%	2-mercaptoethanol	and	boiled	for	
5	 min.	 Antibodies	 anti-GFP	 (JL-8	 Clontech,	 Leusden,	 NL),	 1:5000	 and	 anti-V5	 (Invitrogen,	 CA,	
USA),	1:2000,	were	used	for	detection	on	western	blots.	
	
Production	of	DNAJB6	transgenic	mice.	DNAJB6	transgenic	mice	were	generated	as	described	by	
van	Ree	et	al	(van	Ree	et	al.,	2011).	PCR-amplified	DNAJB6	(human	DNAJB6	isoform	b,	UniProt	KB	
accession	number	O75190-2)	cDNA	with	a	N-terminal	Flag	tag	was	cloned	into	a	unique	BglII	and	
XhoI	 site	 of	 the	 Z/EG	 expression	 vector,	 and	 verified	 by	 sequence	 analysis.	 A	 ScaI-linearized	
vector	 was	 transfected	 into	 ES	 cells	 by	 electroporation	 and	 G418-resistant	 colonies	 with	 high	
expression	levels	of	Flag-DNAJB6	were	selected	as	previously	described	(van	Ree	et	al.,	2011).	ES	
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cells	 were	 karyotyped	 and	 injected	 into	 C57BL/6	 blastocysts	 to	 generate	 chimeric	 animals.	
Chimeric	males	 were	 used	 for	 breeding	 and	 offspring	 were	 screened	 for	 the	 presence	 of	 the	
transgene	by	PCR.	Mice	were	backcrossed	to	C57BL/6	for	at	least	6	generations.	To	excise	the	β-
geo-stop	 cassette	 in	 neurons,	 DNAJB6	 transgenic	mice	were	 bred	 to	Nesting-Cre	mice	 (B6.Cg-
Tg(Nes-cre)1Kln/J;	 Jackson	 Laboratories,	 #003771).	 The	 R6/2	 HD	 mice	 (B6CBA-
Tg(HDexon1)62Gpb/3J;	Jackson	Laboratories,	#006494)	were	from	the	colonies	of	Gillian	Bates.	
	
Mice	handling	and	maintenance.	All	procedures	were	performed	with	approval	of	the	University	
of	 Groningen	 Ethical	 Committee	 for	 Animal	 Experiments,	 which	 adheres	 to	 the	 principles	 and	
guidelines	 established	 by	 the	 European	 Convention	 for	 the	 Protection	 of	 Laboratory	 Animals.	
Experiments	were	 carried	 out	 on	R6/2	mice	 and	DNAJB6	 transgenic	mice	 that	were	 housed	 in	
cages	2-3	mice/cage)	under	conditions	of	standard	cage	enrichment	and	with	ad	libitum	access	
to	food	and	water.	Hemizygous	R6/2	mice	were	bred	by	backcrossing	R6/2	HD	males	to	(CBA	x	
C57Bl/6)	 F1	 females	 (B6CBAF1/OlaHsd,	 Harlan	 Olac).	 The	 genotyping	 and	 CAG	 repeat	
measurements	were	 carried	out	 as	described	previously	 (Mangiarini	 et	 al.,	 1996)	with	primers	
R6/2	 fwd/rev	&	HDAC4	 fwd/rev	used	 for	 genotyping	R6/2	mice	 and	40256	 fwd–40261	 rev	 for	
CAG	 repeat	 sizing	 (Supplementary	 Table	 I).	 The	 presence	 of	 the	 DNAJB6	 transgene	 was	
confirmed	 by	 using	 primer	 pairs	 amplifying	 the	 human	DNAJB6	 transgene,	 NEO	 and	 CRE.	 The	
sequences	of	all	the	primers	used	in	this	study	are	listed	in	Supplementary	Table	I.	
	
Quantitative	PCR.	Total	RNA	was	extracted	 from	 tissue	 samples	by	 the	Trizol	method.	1	μg	of	
total	 RNA	 was	 transcribed	 using	 M-MLV	 reverse	 transcriptase	 (Invitrogen,	 Thermo	 Fisher	
Scientific	 Inc.,	Waltham,	MA,	 USA).	 The	 cDNA	 synthesis	 was	 performed	 with	 oligo	 (dT)	 12-18	
(Invitrogen,	 Thermo	 Fisher	 Scientific	 Inc.,	 Waltham,	 MA,	 USA).	 Relative	 changes	 in	 transcript	
levels	were	determined	on	 the	 Icycler	 (Bio-Rad,	Hercules,	CA,	USA)	using	SYBR	green	supermix	
(Bio-Rad,	 Hercules,	 CA,	 USA).	 Calculations	 were	 done	 using	 the	 comparative	 CT	 method	
according	to	User	Bulletin	2	(Applied	Biosystems,	Foster	City,	CA,	USA).	For	each	set	of	primers,	
the	 PCR	 efficiency	 was	 determined	 standard	 curves	 with	 different	 concentration	 of	 primers.	
Primer	sequences	used	in	this	study	are	listed	in	Supplementary	Table	I.	
	
Immunohistochemistry.	 Dissected	 mouse	 brains	 and	 muscles	 were	 fixed	 in	 4%	 buffered	
formaldehyde,	 followed	 by	 dehydration	 and	 then	 embedded	 in	 paraffin	 and	 sliced	 into	 5	 μm	
sections.	The	sections	were	de-waxed	and	 labelled	with	the	following	antibodies:	EM48	for	Htt	
aggregates	(MAB5374:	Millipore,	Billerica,	MA,	USA),	secondary	biotin	carrying	antibodies	(Dako,	
Carpinteria,	CA,	USA),	an	avidin–biotin–horse	radish	peroxidase	complex	 (ELITE	ABC	Kit,	Vector	
Laboratories,	Burlingame,	CA,	USA)	and	 the	AEC	chromogen	was	added	 for	visualization	under	
bright	 field	 microscopy.	 Nuclear	 counterstaining	 was	 performed	 with	 haematoxylin.	 Control	
sections	without	primary	antibodies	did	not	show	positive	immunostaining.		
	
Behavioural	analysis.	Behavioural	analysis	was	performed	on	an	accelerating	RotaRod	(n	≥	10	for	
HTT	group;	n	≥	9	for	HTT/JB6,	WT	&	JB6	group)	using	female	mice	as	explained	previously	(Hockly	
et	al.,	2003)	with	small	adaptations:	i.e.	a	top	speed	of	40	rpm	over	a	period	of	300	s.	To	maintain	
a	 gap	of	 4	weeks	between	 the	 recordings	 (in	order	 to	 avoid	 learning),	 two	 cohorts	 of	 animals	
were	 used.	 The	 recordings	 from	 4,	 8,	 12,	 16	weeks	 served	 as	 one	 cohort	 and	 from	 6,	 10,	 14	
weeks	as	another	cohort.	At	each	time	point,	the	mice	were	tested	on	three	consecutive	days,	
for	three	trials	per	day.	The	data	are	plotted	as	an	average	of	all	the	trials	for	each	day.	Statistical	
analysis	 was	 performed	 using	 two-way	 ANOVA.	 Clasping	 of	 limbs	was	measured	 as	 described	
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previously	(Chou	et	al.,	2008)	with	n	=	9	for	each	animal	group.	The	mice	were	scored	for	either	
hind	limb	clasping	(referred	to	as	stage	1:	where	one	of	the	hind	limbs	is	clasped	for	over	50%	of	
the	time)	or	full	body	clasp	(referred	to	as	stage	2:	where	both	the	 limbs	were	clasped	around	
the	abdomen	for	more	than	50%	of	the	time)	over	different	age	groups.	Statistical	analysis	was	
performed	 using	 chi-square	 test	 which	 shows	 significant	 difference	 between	 the	 groups	
(*p<0.05,	**p<0.005,	***p<0.001).	Lifespan	was	assessed	by	Kaplan-Meier	analysis.	
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Legends to the Figures 
Figure	 1:	 Aggregation	 suppression	
mechanism	of	DNAJB6	and	 its	mutational	
variants	 showing	 that	 the	 S/T-rich	 region	
is	a	key	structural	 feature	for	 interactions	
with	 polyQ	 nuclei	 and	 inhibition	 of	
primary	 nucleation	 events.	 (A)	 Kinetic	
profiles	 of	 the	 concentration-dependent	
aggregation	 of	 the	 polyQ	 peptide	 at	
concentrations	 of	 10,	 12.8,	 16	 and	 20	 μM	
monitored	by	ThT	fluorescence.	Continuous	
lines	 represent	 global	 fitting	 of	 the	
integrated	 rate	 laws	 to	 the	data	 according	
to	the	equations	described	in	the	Methods	
section.	The	 inset	shows	the	scaling	of	 the	
half-time	 with	 peptide	 concentration,	 the	
value	of	which	 indicates	 the	dominance	of	
a	secondary	nucleation	mechanism	(34-36).	
(B)	Kinetic	profiles	of	the	aggregation	of	15	
μM	 polyQ	 peptide	 in	 the	 absence	 (black)	
and	 presence	 of	 DNAJB6	 (green)	 at	 molar	
ratios	 of	 polyQ:DNAJB6	 of	 1:0.01	 or	 1:0.1;	
the	thin	line	represents	the	fit	of	the	kinetic	
profiles	 according	 to	 Eq.	 {1}	 where	 only	
primary	nucleation	pathways	are	specifically	inhibited	(compare	to	(C)).	(C)	Kinetic	profiles	as	in	
(B),	 showing	 that	 the	 delay	 in	 the	 aggregation	 kinetics	 observed	 in	 the	 presence	 of	 DNAJB6	
cannot	be	described	by	the	integrated	rate	laws	when	secondary	nucleation	pathways	alone	are	
specifically	suppressed	(thin	line),	confirming	that	the	inhibition	activity	of	DNAJB6	results	from	
its	ability	to	interfere	with	primary	nucleation	events	(compare	to	(B)).	(D)	Amino	acid	sequences	
of	wild-type	(WT)	DNAJB6	with	the	S	and	T	residues	underlined,	and	of	the	mutational	variants	
(M1-M3)	with	5,	13	and	18	S/T-to-A	substitutions	underlined,	and	of	a	Δ132-183	deletion	mutant	
variant	(M4).	(E)	Kinetic	profiles	of	the	aggregation	of	polyQ	peptide	(Q45)	at	a	concentration	of	
15	μM	in	the	presence	of	DNAJB6	WT	(green)	or	its	mutational	variants	M1	(red),	M2	(turquoise),	
M3	 (orange),	 and	 M4	 (blue)	 at	 molar	 ratios	 of	 polyQ	 to	 DNAJB6	 of	 1:0.01	 and	 1:0.1.	 The	
continuous	lines	represent	fits	of	the	integrated	rate	laws	to	the	data	in	which	inhibition	of	both	
primary	 and	 secondary	 nucleation	 events	 has	 been	 considered	 simultaneously.	 (F,	 G)	 The	
decreases	 in	 the	 rates	 of	 primary	 nucleation	 and	 secondary	 nucleation,	 respectively,	
corresponding	 to	 the	 reaction	 profiles	 in	 (E)	 for	WT	 DNAJB6	 and	 for	 the	M1-M4	 variants,	 all	
normalized	to	the	values	in	the	absence	of	chaperone.	The	fluorescence	data	used	for	all	kinetic	
analyses	 are	 presented	 in	 Fig.	 S5.	 (H)	 Structural	 model	 of	 a	 DNAJB6	monomer,	 generated	 as	
described	in	Fig.	S4,	showing	the	conserved	serine	(S)	and	threonine	(T)	residues	(pink)	exposed	
on	one	side	of	the	DNAJB6	structure.	(I)	The	amount	of	DNAJB6	and	mutational	variants	M1-M4	
of	 DNAJB6	 binding	 to	 and	 captured	 in	 polyQ	 fibrils	 trapped	 on	 filter	 and	 probed	 by	
immunofluorescence	(starting	concentrations	15	µM	polyQ	peptide;	upper	row	1.5	µM	DNAJB6	
or	 variants,	 lower	 row	 0.15	µM	DNAJB6	 or	 variants).	 (J)	 Quantitation	 of	 immunofluorescence	
data	in	(I);	data	from	3	experiments	(mean	±	SD).	
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Figure	2:	Comparison	of	the	effects	of	DNAJB6	on	seeded	and	non-seeded	aggregation	in	cells.	
HEK293	 cells	 expressing	 Htt-Q23-eGFP	 or	 Htt-Q74-eGFP	 intracellularly,	 with	 or	 without	 V5-
DNAJB6	 co-expression,	 were	 exposed	 to	 1	 μM	 aliquots	 of	 polyQ	 peptide	 in	 aggregated	 and	
fibrillar	forms	([Q45	seeds]extra)	that	was	added	to	the	medium.	(A)	EM	image	of	the	Q45	seeds	
used.	(B)	Representative	confocal	pictures	of	cells	co-transfected	with	DNAJB6	and	HttQ23-eGFP	
(green)	or	HttQ74-eGFP	(green),	incubated	without	(-)	or	with	(+)	[Q45	seeds]extra	in	the	medium.	
DAPI	 staining	 is	 shown	 in	 blue.	 (C)	 Western	 blots	 of	 the	 same	 cell	 extracts	 as	 in	 panel	 (B).	
Nitrocellulose	membranes	were	probed	with	the	antibodies	indicated.	(D)	Filter	trap	assay	of	the	
same	 cell	 extracts	 as	 in	panel	 (A),	 taken	at	 the	 indicated	 time	points	 after	 the	 addition	of	 the	
[Q45	seeds]extra.	 Three	 serial	 five-fold	dilutions	were	 loaded	onto	cellulose-acetate	membranes	
and	probed	with	anti-GFP	antibodies	to	detect	aggregation	of	the	 intracellularly	expressed	Htt-
Q23-eGFPintra	 or	Htt-Q74-eGFPintra.	 As	 a	 control,	 [Q45	 seeds]extra	were	directly	 added	 after	 lysis	
(post	 lysis)	 and	 showed	 no	 aggregates.	 Cells	 expressing	 Htt-Q74-eGFPintra	 show	 the	 effective	
suppression	 of	 intracellularly	 generated	 aggregates	 by	 DNAJB6,	without	 the	 addition	 of	 polyQ	
peptide	in	aggregated	and	fibrillar	forms	([Q45	seeds]extra).	(E)	Quantification	of	the	data	in	panel	
C;		data	are	the	mean	±	s.e.m.	of	3	independent	experiments.	
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Figure	 3:	 Effects	 of	 mutations	 in	 the	 S/T-rich	 region	 of	 DNAJB6	 on	 its	 ability	 to	 prevent	
aggregation	of	 polyQ	 in	 cells.	HEK293	 cells	were	 transfected	with	 exon-1	Htt-Q119-eYFP	 (Htt-
Q119)	without	(C,	black)	or	with	the	wildtype	V5-DNAJB6	(WT,	green)	or	the	mutational	variants	
having	5	(M1,	red),	13	(M2	(turquoise)	or	18	(M3,	orange)	S/T-to-A	substitutions	in	the	S/T-rich	
region	of	DNAJB6,	or	a	Δ132-183	deletion	mutational	variant	(M4,	blue)	(see	figure	1F).	Samples	
were	 analyzed	 24	 h	 after	 transfection.	 (A)	 Representative	 immunofluorescent	 pictures	 of	 cells		
transfected	 with	 HttQ119-eYFP	 without	 (C)	 or	 with	 the	 wildtype	 (WT)	 or	 the	 various	 DNAJB6	
mutational	variants	(M1-M4).	(B)	Western	blot	of	cell	extracts.	Nitrocellulose	membranes	were	
probed	with	the	antibodies	indicated,	showing	expression	of	the	wild	type	DNAJB6	(WT)	and	the	
M1-M4	mutational	 variants	 using	 an	 anti-V5	 antibody.	 Soluble	 (sol)	 and	 aggregated	Htt-Q119-
eYFP	(stack)	(anti-GFP)	are	also	depicted.	GAPDH	is	provided	as	a	loading	control.	(C)	Serial	five-
fold	dilutions	of	the	same	extracts	as	in	panel	B	were	loaded	onto	cellulose-acetate	membranes	
and	 probed	with	 an	 anti-GFP	 antibody	 to	 detect	 aggregation	 Htt-Q119-eYFP.	 (D)	 Quantitative	
analysis	 of	 the	 images	 in	 panel	 A,	 expressing	 the	 fraction	 of	 cells	 containing	 inclusions	 (2	
experiments,	 each	 scored	 by	 at	 least	 3	 independent	 observers	 and	 then	 averaged).	 (E)	 The	
amount	of	high	molecular	weight	aggregated	(HMW)	polyQ	proteins	 in	panel	B	relative	to	cells	
without	 chaperones	 (=	100)	 from	2	 independent	experiments	 (mean	±	 SD).	 (F)	 The	amount	of	
aggregates	captured	on	cellulose	acetate	(panel	C)	relative	to	cells	without	chaperones	(=	100)	
from	2	independent	experiments	(mean	±	SD).	
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Figure	 4:	 DNAJB6	 suppresses	 the	 formation	 of	 polyQ	 aggregates	 and	 the	 effect	 of	 polyQ	
expression	 on	 neurite	 formation	 even	 before	 histologically	 visible	 aggregation	 in	 neuronal	
cells.	Differentiated	NG108	cells	were	transfected	with	exon-1	Htt-Q119-eYFP	(Htt-Q119)	with	or	
without	 V5-DNAJB6	 or	 the	 V5-tagged	 DNAJB6	 M3	 variant	 with	 18	 S/T-to-A	 substitutions.	 (A)	
Serial	 five-fold	 dilutions	 of	 the	 cell	 extracts	 in	 SDS-buffer	 were	 loaded	 onto	 cellulose-acetate	
membranes	and	probed	with	an	anti-GFP	antibody	to	detect	aggregation	Htt-Q119-eYFP	and	(B)	
quantified	by	densitometry	(mean	+	SD	of	2	experiments).	(C)	Representative	confocal	images	of	
differentiated	 NG108	 cells	 co-transfected	 with	 Htt-Q119-eYFP	 (green)	 and	 DNAJB6	 with	
additional	staining	of	β-III	tubulin	(red)	and	DAPI	(blue).	(D)	Individual	cells	(approx.	60	cells	per	
condition)	 were	 manually	 counted	 to	 identify	 neurite	 (dendritic)	 processes.	 Cells	 with	 and	
without	 aggregation	 of	 polyQ	 were	 scored	 independently.	 *P<0.05,	 **P<0.01,	 ***P<0.001;	
Kruskal-Wallis	test	with	Dunn’s	post	hoc	test.	 	(E)	FRAP	analysis	for	NG108	cells	expressing	Htt-
Q119-eYFP	alone	or	together	with	RFP-DNAJB6	or	the	V5-DNAJB6	H/Q	mutant	(that	is	unable	to	
interact	with	Hsp70),	analyzed	12	h	post	transfection	and	before	the	aggregates	were	visible.	
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Figure	 5:	 Effects	 of	 an	 HPD	mutation	
on	 the	 ability	 of	 DNAJB6	 to	 prevent	
aggregation	 of	 polyQ	 in	 cells.	 	 (A)	
HEK293T	 cells	 were	 co-transfected	
with	 Htt-Q119-YFP	 constructs	 with	
either	 an	 empty	 vector	 or	 with	 V5-
DNAJB6b	 WT,	 V5-DNAJB6b	 H31Q	 or	
V5-DNAJB6b	 M3	 constructs.	 Cell	
lysates	 were	 treated	 with	 a	 chemical	
cross-linker	 and	 cross-linked	 material	
(input)	 was	 precipitated	 using	 GFP-
Trap	 magnetic	 beads	 (IP:GFP)	 and	
analysed	 by	 westerns	 blotting.	 	 (B)	
Same	 as	 A,	 but	 using	 GFP-tagged	
HSPA1A.	 (C-F)	 HEK293	 cells	 were	
transfected	with	exon-1	Htt-Q119eYFP	
(Htt-Q119)	 without	 (C,	 black)	 or	 with	
the	 wildtype	 V5-DNAJB6	 (WT-HPD,	
green	 solid),	 DNAJB6	with	 a	mutation	
in	 the	HPD	motif	of	 the	 J-domain	that	
disrupts	 its	 interaction	 with	 Hsp70	
(WT-QPD,	 green	 open)	 or	 with	 the	
DNAJB6	 mutational	 variant	 with	 13	
S/T-to-A	 substitutions	 in	 the	 S/T-rich	
region,	 either	 alone	 (M2-HDP,	
turquoise	 solid)	 or	 combined	 with	 a	
mutation	 in	 the	 J-domain	 (M2-QDP,	
turquoise	 open).	 Samples	 were	
analyzed	 24	 h	 after	 transfection.	 (C)	
Western	blot	of	extracts	from	cells	co-
transfected	 with	 exon-1	 Htt-Q119-
eYFP	 (Htt-Q119)	 and	 the	 indicated	
DNAJB6	 variants.	 Nitrocellulose	
membranes	 were	 probed	 with	 the	
antibodies	 indicated,	 showing	 expression	 of	 the	 different	 DNAJB6	 variants	 using	 an	 anti-V5	
antibody,	 soluble	 (sol)	 and	 aggregated	 Htt-Q119-eYFP	 (stack)	 depicted	 using	 an	 anti-GFP	
antibody	and	an	anti-GAPDH	antibody	provided	as	loading	control.	(D)	Serial	five-fold	dilutions	of	
the	same	extracts	as	in	panel	B	were	loaded	on	cellulose-acetate	membranes	and	probed	with	an	
anti-GFP	 antibody	 to	 detect	 aggregated	Htt-Q119-eYFP.	 (E)	 Representative	 immunofluorescent	
pictures	of	cells	transfected	with	HttQ119-eYFP	without	or	with	the	various	DNAJB6	constructs.	
(F)	Quantitative	analysis	of	the	images	like	in	panel	D,	expressing	the	fraction	of	cells	containing	
inclusions	 from	 4	 experiments,	 each	 scored	 by	 at	 least	 3	 independent	 observers	 and	 then	
averaged	 (mean	 ±	 sem).	 (G)	 The	 amount	 of	 high	molecular	 weight	 aggregated	 (HMW)	 polyQ	
proteins	 in	 panel	 B	 relative	 to	 cells	 without	 chaperones	 (=100)	 from	 3-5	 independent	
experiments	(mean	±	sem).	(H)	The	amount	of	aggregates	captured	on	cellulose	acetate	(panel	C)	
relative	to	cells	without	chaperones	(=	100)	from	3-5	independent	experiments	(mean	±	sem).	
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Figure	6:	Generation	of	DNAJB6	transgenic	mice	and	the	reduction	of	HTT	aggregate	formation	
in	mouse	brains.	(A)	Floxed	DNAJB6	transgenic	mice	were	produced	as	described	in	the	Methods	
and	Results	sections	and	the	active	 transgene	was	generated	after	crossing	with	Nes-CRE	mice	
for	 specific	 expression	of	DNAJB6	 in	 the	brains	 of	 the	 animals.	 (B)	mRNA	 levels	 of	 the	human	
DNAJB6	 transcript	 relative	 to	 GAPDH	 from	 a	 range	 of	 tissues	 from	 both	 DNAJB6	 transgenic	
(TgDNAJB6:	 green	 bar)	 and	 wild	 type	 (WT:	 black	 bar)	 animals.	 (C)	 Level	 of	 hDNAJB6	 protein	
expression	 in	 the	 brain,	 liver,	 and	 kidney	 in	 two	 TgDNAJB6	 mice	 and	 one	 WT	 mouse.	 (D)	
Huntingtin	 aggregation	 in	 whole	 brain	 lysates	 was	 found	 to	 be	 reduced	 in	 HTT/JB6	 double	
transgenic	mice	compared	to	HTT	mice	at	all	time	points.	The	S829	antibody	was	used	to	detect	
both	HTT	aggregates	 (agg:	 in	stacking	gel)	and	soluble	HTT	(sol).	 (E)	Relative	 levels	of	 insoluble	
HTT	were	plotted	using	GAPDH	as	a	loading	control	and	setting	values	for	the	HTT	mice	at	100%	
(±	sem)	for	each	time-point	(n=3	for	each	group).	The	statistical	significance	was	analysed	using	
an	 independent	 t-test	 (***	 P=0.0005,	 **	 P=0.007).	 (D)	 Representative	 immunohistochemical	
images	of	the	striatum	of	HTT	and	HTT/JB6	mice	at	various	time	points.	Hematoxylin	was	used	as	
a	nuclear	counterstain	(blue)	and	EM48	as	a	means	of	visualizing	HTT	aggregates	(brown).	Scale	
bar	=:	100	µm.	(E)	The	percentage	of	inclusion	positive	nuclei;	values	are	the	mean	±	sem	from	3	
animals	 per	 group;	 for	 each	 sample,	 30-40	 nuclei	 were	 counted	 for	 HTT	 aggregates.	 The	
statistical	 significance	 of	 the	 results	 was	 analyzed	 using	 an	 independent	 t-test	 (**P<0.008,	
*P<0.05).	
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Figure	7:	 Effect	of	DNAJB6	overexpression	on	disease	onset	 in	an	R6/2	mouse	model	of	HTT	disease.	
Control	wildtype	mice	 (WT:	 bleu),	DNAJB6	 transgenic	mice	 (JB6:	 red),	 R6/2	mice	 (HTT:	 black)	 and	R6/2	
mice	x	DNAJB5	mice	(HTT/JB6:	green)	were	analyzed	at	the	indicated	time	points	for:	(A)	Performance	on	
a	 rorarod,	 where	 the	 latency	 time	 that	 each	 animal	 stayed	 on	 the	 rotating	 rod	 before	 falling	 was	
monitored	in	3	trials	per	day	for	3	consecutive	days	for	each	group.	The	mean	±	sem	values	of	the	three	
trials	on	each	day	are	plotted.	Data	were	tested	for	normality	by	using	Komogorov-Smirnov	normality	test	
and	was	compared	using	 two-way	ANOVA	 followed	by	a	Holm-Sidak	Post-hoc	 test.	Data	was	extremely	
significant	for	HTT	versus	HTT/JB6	at	12	wks	of	age	(****p<0.0001).	No	statistical	differences	were	found	
between	control	groups	(WT	and	JB6).	(B)	Hind	 limb	clasping	and	 (C)	 full	body	clasping	scored	between	
HTT	 and	 HTT/JB6	 group.	 Chi-Square	 test	 for	 contingency	 was	 performed	 representing	 *p<0.05,	
**p<0.005,	 ***p<0.001	 significance.	 (D)	 Kaplan-Meier	 plot	 for	 progression	 free	 survival	 (>20%	 weight	
loss).	Animals	with	more	than	20%	weight	loss	were	sacrificed	(50%	survival	is	at	13.5	weeks	for	HTT	mice	
and	17.5	weeks	for	HTT/JB6	mice,	implying	a	23%	increase	in	life	span	for	the	latter).<Vaishali:	please	add	
statement	on	the	statistics	here>	
